eicosapentaenoic acid ethyl ester has been researched along with eicosapentaenoic acid in 395 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (4.05) | 18.7374 |
| 1990's | 56 (14.18) | 18.2507 |
| 2000's | 60 (15.19) | 29.6817 |
| 2010's | 155 (39.24) | 24.3611 |
| 2020's | 108 (27.34) | 2.80 |
| Authors | Studies |
|---|---|
| Kasanuki, J; Kitsukawa, Y; Saito, H; Suzuki, Y; Tamura, Y; Yoshida, S | 1 |
| Hamazaki, T; Yamazaki, K | 1 |
| Hirano, K; Kubo, M; Matsuzawa, Y; Nozaki, S; Sakai, N; Tarui, S | 1 |
| Isaka, M; Mizutami, M; Okuda, Y; Tanaka, K; Yamashita, K | 1 |
| Matsuda, Y; Otsuka, M; Teraoka, R | 2 |
| Chang, KJ; Saito, H; Saito, I; Tamura, Y; Yoshida, S | 1 |
| Bakken, AM; Farstad, M; Holmsen, H | 1 |
| Colli, S; Galli, C; Maderna, P; Mosconi, C; Sirtori, CR; Stragliotto, E; Tremoli, E | 1 |
| Chang, KJ; Saito, H; Tamura, Y; Tatsuno, I; Yoshida, S | 1 |
| Silver, MJ; Walker, J; Wojenski, CM | 1 |
| Chang, KJ; Saito, H; Tamura, Y; Yoshida, S | 1 |
| Edwards, TJ; Filipowicz, BL; Hawkey, CJ; Hawthorne, AB | 1 |
| Hamazaki, T; Osawa, K; Takazakura, E; Urakaze, M; Yano, S | 1 |
| Chang, KJ; Saito, H; Tamura, Y; Watanabe, K; Yoshida, S | 1 |
| Falardeau, P; Hui, R; St-Louis, J | 1 |
| Fujikawa, M; Fujita, T; Hamazaki, T; Kaneda, M; Sawazaki, S; Taki, H; Urakaze, M; Yamazaki, K; Yano, S | 1 |
| Ito, M; Kawasaki, N; Matsui, K; Nakamura, T; Okamura, H; Yoshimura, T; Yunohara, T | 1 |
| Colvin, RB; Hirai, A; Robinson, DR; Steinberg, AD | 1 |
| Endo, S; Kanehiro, H; Katsuki, Y; Kojima, M; Miyata, H; Mizota, M; Mizuguchi, K; Okada, M; Serizawa, K; Takase, A | 1 |
| Endo, S; Ishiguro, J; Kanehiro, H; Katsuki, Y; Kojima, M; Miyata, H; Mizota, M; Mizuguchi, K; Okada, M; Takase, A | 1 |
| Aizawa, N; Ida, K; Ishiguro, J; Kosuzume, H; Ogihara, T; Ohzawa, N; Tada, T | 1 |
| Ishiguro, J; Kosuzume, H; Murakami, K; Ogihara, T; Ohzawa, N; Tada, T | 1 |
| Kamido, H; Matsuzawa, Y; Tarui, S | 1 |
| Aizawa, N; Ishiguro, J; Kosuzume, H; Mizota, M; Mizuguchi, K; Ogihara, T; Ohzawa, N; Tada, T | 1 |
| Hirai, A; Patel, B; Robinson, DR; Tateno, S | 1 |
| Fujita, T; Hamazaki, T; Kobayashi, S; Urakaze, M; Yano, S | 1 |
| Hirai, A; Lam, BK; Marcinkiewicz, E; Quilley, J; Tamura, Y; Wong, PY; Yoshida, S | 1 |
| Hashimoto, Y; Hayashi, H; Kato, H; Kawamura, M; Matsushima, T; Naito, C | 1 |
| Fujita, T; Hamazaki, T; Hirai, A; Kondo, S; Kumagai, A; Sajiki, J; Tamura, Y; Terano, T | 1 |
| Mori, M; Ohtani, K; Sato, N; Shimizu, H; Shimomura, Y; Tanaka, Y | 1 |
| Ito, H; Kotake, T; Nomura, K | 1 |
| Akahane, N; Nakahara, T; Ohba, S; Ohshima, N; Suzuki, J; Wakabayashi, T; Yanagi, K | 1 |
| Akada, Y; Iimura, M; Kanehiro, H; Katsuki, Y; Kunihiro, Y; Mizota, M; Sato, M | 1 |
| Hirose, K; Kako, K; Matsushita, K; Nakamura, S; Sakakibara, H; Sato, M; Suetsugu, S | 1 |
| Aoyama, T; Saga, T; Takekoshi, T | 2 |
| Fujikawa, M; Hamazaki, T; Kobayashi, M; Koizumi, F; Wakaki, K; Yamazaki, K; Yano, S | 1 |
| Berti, MA; Borella, F; Braga, PC; Piatti, G | 1 |
| Chapkin, RS; Fowler, KH; McMurray, DN | 1 |
| Angeli, MT; Colli, S; Eligini, S; Galli, C; Marangoni, F; Sirtori, CR; Tremoli, E | 1 |
| Aukema, HM; Chapkin, RS; Fan, YY; Fowler, KH; McMurray, DN | 1 |
| Kashima, K; Mori, M; Ohtani, K; Sato, N; Shimizu, H; Tanaka, Y | 1 |
| Aoyama, T; Saga, T | 1 |
| Fukuhara, K; Hamada, Y; Katsuki, Y; Kawano, H; Kunihiro, Y; Mizota, M; Sato, M | 1 |
| Knoell, CT; Olesiak, W; Robinson, DR; Tateno, S; Xu, LL | 1 |
| Colvin, RB; Guo, M; Robinson, DR; Tateno, S; Xu, LL | 1 |
| Fukutake, K; Ishibashi, M; Masada, A; Mizota, M; Mizuguchi, K; Saito, Y; Tanaka, Y; Yano, T | 1 |
| Akkerman, JW; Banga, JD; de Graaf, JC; Erkelens, DW; Sixma, JJ; van Breugel, HH; Westerveld, HT | 1 |
| Ishibashi, M; Masada, A; Mizota, M; Mizuguchi, K; Saito, Y; Yano, T | 1 |
| Mizuguchi, K; Sato, M; Takasugi, K; Tanaka, Y; Yano, T | 1 |
| Spiller, RC; Thompson, L | 1 |
| Fukatsu, A; Mori, M; Ohtani, K; Sato, N; Shimizu, H; Tanaka, Y; Uehara, Y | 1 |
| Asano, T; Futata, T; Kan, K; Miwa, H; Yamamoto, M | 1 |
| Marignani, PA; Sebaldt, RJ | 1 |
| Kaiga, K; Miyao, Y; Ogawa, H; Sakamoto, T; Tanae, H; Tsuruta, K; Yasue, H | 1 |
| Framstad, T; Rest, JR; Taugbøl, O | 1 |
| Asano, M; Kawashima, K; Nakajima, T; Okuda, Y; Sawada, T; Soma, M; Suzuki, S; Tsurumaru, K; Yamashita, K | 1 |
| Akimoto, M; Hashimoto, H; Ishiguro, H; Kikuchi, Y; Kurihara, T; Maeda, A; Niimi, A; Shigemoto, M; Tsuchiya, M; Yamashita, K; Yokoyama, I | 1 |
| Akahane, N; Nakahara, T; Ohba, S; Ohshima, N; Wakabayashi, T; Yanagi, K; Yokochi, T | 1 |
| Ito, M; Matsui, K; Okamura, H; Yoshimura, T | 1 |
| Katayama, Y; Katsumata, T; Muramatsu, H; Obo, R; Terashi, A; Usuda, K | 1 |
| Iwamoto, T; Kawano, H; Mizuguchi, K; Mochizuki, H; Yamashita, M; Yano, T | 1 |
| Hata, S; Ikeda, Y; Ishikawa, T; Katoh, S; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J | 1 |
| Abei, M; Kawano, H; Mizuguchi, K; Tanaka, N; Yano, T | 1 |
| Hata, N; Kobayashi, T; Misawa, Y; Ohhashi, K; Okuyama, H; Takahashi, T; Watanabe, S | 1 |
| Asano, T; Hayakawa, M; Nakamura, H; Suzuki, S; Tokonabe, S | 1 |
| Katayama, Y; Katsumata, T; Muramatsu, H; Obo, R; Ohtori, T; Terashi, A | 1 |
| Ikeda, Y; Ishikawa, T; Mori, Y; Murakawa, Y; Nobukata, H; Shibutani, Y; Tajima, N; Yokoyama, J | 1 |
| Ando, M; Nihei, H; Sanaka, T | 1 |
| Li, X; Xiao, Y | 1 |
| Bartoli, GM; Calviello, G; Di Nicuolo, F; Maggiano, N; Palozza, P | 1 |
| Dagnelie, PC; Rietveld, T; van den Berg, JW; Wilson, JH; Zuijdgeest-van Leeuwen, SD | 1 |
| Bezuglov, VV; Bobrov, MY; Fomina-Ageeva, EV; Gretskaya, NM; Kuklev, DV; Nagaev, IY; Remov, MN; Rogov, SI; Shevchenko, VP; Yudushkin, IA | 1 |
| Ishikawa, T; Nobukata, H; Obata, M; Shibutani, Y | 2 |
| Hishinuma, T; Ishizawa, F; Mizugaki, M; Yamazaki, T | 1 |
| Kurabayashi, T; Okada, M; Tanaka, K | 1 |
| Dagnelie, PC; Swart, GR; Van den Berg, JW; Van der Gaast, A; Wattimena, JL; Wilson, JH; Zuijdgeest-Van Leeuwen, SD | 1 |
| Iguchi, M; Konya, E; Kurita, T; Tsuji, H; Umekawa, T | 1 |
| Gu, JY; Hung, P; Ikeda, I; Kaku, S; Ohkura, K; Sugano, M; Tachibana, H; Yamada, K; Yazawa, K; Yunoki, S | 1 |
| Tsushima, M | 1 |
| Fujiwara, K; Imamura, S; Itoh, M; Iwase, K; Kato, T; Makino, M; Miura, N; Nagasaka, A; Oda, N; Sawai, Y; Yamamoto, K | 1 |
| Boronow, J; Dickerson, F; Fenton, WS; Hibbeln, JR; Knable, M | 1 |
| Endo, T; Itou, S; Iwamoto, T; Iwata, N; Shimizu, T; Takasaki, M | 1 |
| Belmaker, RH; Nemets, B; Stahl, Z | 1 |
| Ishimura, N; Mawatari, K; Minami, A; Nakaya, Y; Okada, K; Sakamoto, S; Takishita, E | 1 |
| Appel, C; Bydder, GM; Corridan, BJ; Counsell, SJ; Hajnal, JV; Horrobin, DF; Mckee, HM; Puri, BK; Richardson, AJ; Vaddadi, KS | 1 |
| Eizawa, T; Hattori, Y; Matsuda, M; Nakajima, K | 1 |
| Ito, T; Kushihata, S; Masaki, T; Nishida, Y; Oda, H; Taniguchi, Y; Yamakido, M; Yorioka, N | 1 |
| Horrobin, DF; Peet, M | 1 |
| Horrobin, DF | 2 |
| Hotta, O; Ieiri, N; Taguma, Y | 1 |
| Imamura, K; Matsumura, Y; Mizutani, Y; Mori, T; Nakanishi, K | 1 |
| Frankenburg, FR; Zanarini, MC | 1 |
| Fu, JM; Lao, BS; Min, YS; Sheng, GY; Wen, KW; Zhang, G | 1 |
| Chiu, CC; Huang, SY; Shen, WW; Su, KP | 1 |
| Fokkema, MR; Horrobin, D; Muskiet, FA | 1 |
| Gil, A | 1 |
| Fujii, T; Igarashi, J; Nagata, S; Ohtsuka, Y; Shimizu, T; Suzuki, R; Yamashiro, Y | 1 |
| Harada, T; Kasahara, T; Mori, Y; Nobukata, H; Tajima, N | 1 |
| Hong, DD; Ide, T; Kushiro, M; Takahashi, Y | 1 |
| Horrobin, DF; Leonard, BE; Phillips, AG; Song, C | 1 |
| Horrobin, DF; Murck, H; Song, C; Uhr, M | 1 |
| Horrobin, D; Song, C | 1 |
| Horrobin, DF; Leonard, BE; Song, C | 1 |
| Ayton, AK; Azaz, A; Horrobin, DF | 1 |
| Bennett, A; Bennett, CN; Boston, PF; Horrobin, DF | 1 |
| Matsumura, Y; Mori, T; Murakami, H; Park, EY | 1 |
| Greenamyre, JT; Hayden, MR; Hersch, S; Horrobin, DF; Leavitt, BR; Manku, M; Murck, H; Puri, BK; Rosenblatt, A; Ross, CA; Sword, A; Vaddadi, KS | 1 |
| Kimura, Y; Sumiyoshi, M | 1 |
| Barakauskas, VE; Barr, AM; Hayden, MR; Honer, WG; Leavitt, BR; Lu, G; Pearson, J; Rogers, DA; Van Raamsdonk, JM | 1 |
| Matsumura, Y; Murakami, H; Park, EY | 1 |
| Kakinuma, C; Naba, H; Ogihara, T; Ohnishi, S | 1 |
| Amminger, GP; Berger, GE; Smesny, S | 1 |
| Altshuler, LL; Denicoff, KD; Duan, N; Freeman, MP; Frye, MA; Grunze, H; Keck, PE; Kupka, R; Leverich, GS; McElroy, SL; Mintz, J; Nolen, WA; Post, RM; Suppes, T | 1 |
| Upton, I | 1 |
| Frangou, S; Lewis, M; Simmons, A; Wollard, J | 1 |
| Manku, M; Murck, H | 1 |
| Amminger, GP; Berger, GE; Brewer, W; McConchie, M; McGorry, PD; Proffitt, TM; Wood, SJ; Yuen, H | 1 |
| Amminger, GP; Berger, GE; Jackson, GD; McConchie, M; McGorry, PD; Pantelis, C; Proffitt, TM; Velakoulis, D; Wellard, RM; Wood, SJ | 1 |
| Fujisawa, H; Kato, S; Kurokawa, T; Shirao, S; Suzuki, M; Yoneda, H | 1 |
| Gotlinger, KH; Kruger, MC; Poulsen, RC; Serhan, CN | 1 |
| Marcos-Gómez, B; Martínez, JA; Moreno-Aliaga, MJ; Pérez-Echarri, N; Pérez-Matute, P | 1 |
| Morishita, M; Shida, T; Takayama, K; Tanaka, T | 1 |
| Ashmore, JH; Harris, KA; Harris, WS; Larson, MK; Pottala, JV; Sprehe, M; Vogelaar, JL | 1 |
| Asselin, G; Dodin, S; Lucas, M; Mérette, C; Poulin, MJ | 1 |
| Manku, M; Song, C; Zhang, XY | 1 |
| Harada, T; Imada, K; Kajikawa, S; Kawashima, A; Mizuguchi, K | 1 |
| Agoston, AM; Alpert, JE; Beaumont, EC; Dahan, LE; Dording, CM; Farabaugh, AH; Fava, M; Mischoulon, D; Nierenberg, AA; Papakostas, GI; Smith, J; Sonawalla, SB | 1 |
| Belevych, AE; Billman, GE; Carnes, CA; Gyorke, S; Haizlip, KM; Harris, WS; Hiranandani, N; Janssen, PM; Monasky, MM; Nishijima, Y; Terentyev, D; Xu, Y | 1 |
| Berger, GE; Cocchi, L; Jackson, GD; McConchie, M; McGorry, PD; Pantelis, C; Proffitt, TM; Takahashi, T; Wood, SJ | 1 |
| Calder, PC; Cawood, AL; Ding, R; Gallagher, PJ; Grimble, RF; Gudmundsen, O; Napper, FL; Payne, SP; Shearman, CP; Vige, R; Ward, MJ; Williams, JA; Ye, S; Young, RH | 1 |
| Zampelas, A | 1 |
| El Bahh, B; Luchtman, DW; Meng, Q; Song, C; Yang, J; Zidichouski, JA | 1 |
| Assies, J; Beekman, AT; Bot, M; de Jonge, P; Jansen, EH; Pouwer, F | 1 |
| Ballantyne, CM; Bays, HE; Braeckman, RA; Isaacsohn, JL; Kastelein, JJ; Soni, PN | 1 |
| Leavitt, BR; Sivananthan, SN | 1 |
| Gamoh, S; Haque, AM; Hashimoto, M; Katakura, M; Shahdat, H; Shido, O; Tanabe, Y; Tozawa, R | 1 |
| Luchtman, DW; Meng, Q; Song, C | 1 |
| Ballantyne, CM; Bays, HE; Braeckman, RA; Isaacsohn, JL; Kastelein, JJ; Soni, PN; Stein, E | 1 |
| Jacobson, TA | 1 |
| Alessandri, M; Attorri, L; Calzà, L; Di Benedetto, R; Di Biase, A; Lorenzini, L; Salvati, S; Sanchez, M | 1 |
| Ballantyne, CM; Braeckman, RA; Soni, PN | 1 |
| Ballantyne, CM; Bays, HE; Braeckman, RA; Brinton, EA; Kastelein, JJ; Soni, PN | 1 |
| Hashimoto, M; Hossain, S; Inoue, T; Katakura, M; Shido, O; Tanabe, Y; Tsuchikura, S | 1 |
| Anderson, GL; Booth-Laforce, C; Caan, B; Carpenter, JS; Cohen, LS; Ensrud, KE; Freeman, EW; Freeman, M; Guthrie, KA; Joffe, H; LaCroix, AZ; Larson, JC; Learman, LA; Manson, JE; Newton, KM; Reed, SD; Sternfeld, B; Tinker, LF | 1 |
| Bays, HE; Braeckman, RA; Manku, MS; Soni, PN; Stirtan, WG | 1 |
| Cassagnol, M; Ezzo, D; Patel, PN | 1 |
| Munger, MA; Nelson, SD | 1 |
| Bentsen, H; Bøhmer, T; Osnes, K; Refsum, H; Solberg, DK | 1 |
| Hiatt, WR; Smith, RJ | 1 |
| Hirakawa, E; Janjua, N; Kabuto, H; Mankura, M; Takayama, F; Yamanushi, TT | 1 |
| Braeckman, RA; Soni, PN; Stirtan, WG | 3 |
| Abdelmalek, MF; Chojkier, M; Cummings, OW; Sanyal, AJ; Suzuki, A | 1 |
| Castaldo, RS | 1 |
| Begemann, MJ; de Haan, L; Schulte, PF; Veerman, SR | 1 |
| Tatsuno, I | 1 |
| Bouskela, E; Conde, CM; de Souza, Md; Laflôr, CM; Sicuro, FL | 1 |
| Weintraub, HS | 1 |
| Kim, ES; McCormack, PL | 1 |
| Levesque, A; Lisi, L; Navarra, P; Scarsi, C | 1 |
| Caffrey, MK | 1 |
| Nicholls, SJ; Scherer, DJ | 1 |
| Nakamura, M | 1 |
| Ballantyne, CM; Bays, HE; Braeckman, RA; Doyle, RT; Juliano, RA; Philip, S; Soni, PN; Stirtan, WG | 2 |
| Gębski, P; Grancow, M; Kotlicka-Antczak, M; Pawełczyk, A; Pawełczyk, T; Szemraj, J; Trafalska, E; Żurner, N | 1 |
| Craufurd, D; Ferreira, JJ; Landwehrmeyer, B; Mallard, N; Rosser, A; Squitieri, F | 1 |
| Charo, A; Sharfstein, JM | 1 |
| Kedia, AW; Lynch, E | 1 |
| Grancow-Grabka, M; Kotlicka-Antczak, M; Pawełczyk, A; Pawełczyk, T; Trafalska, E | 1 |
| Gose, T; Kamo, S; Nakanishi, T; Otake, K; Shimada, H; Tamai, I | 1 |
| Kapczynski, A | 1 |
| Sklan, A | 1 |
| Habe, K; Higashiyama, A; Mizutani, H; Omoto, Y; Yamanaka, K; Yokoyama, T | 1 |
| Hey, SP; Kesselheim, AS | 1 |
| Cunha, GM; Factor-Litvak, P; Farias, DR; Kac, G; Lepsch, J; Pinto, TJ; Vaz, JS; Vilela, AA | 1 |
| Chowdhury, S; Reddy, KJ | 1 |
| Fialkow, J | 1 |
| Ballantyne, CM; Bays, HE; Doyle, RT; Juliano, RA; Philip, S | 1 |
| Baik, SJ; Cho, JH; Choi, IY; Jeong, YJ; Kim, H; Kim, HS; Lee, H; Lee, SH; Yang, SJ; Yim, HW; Yoon, KH | 1 |
| Anzalone, D; Backes, J; Catini, J; Hilleman, D | 1 |
| Crandell, JR; Tartaglia, C; Tartaglia, J | 1 |
| Ballantyne, CM; Bays, HE; Doyle, RT; Guyton, JR; Juliano, RA; Mosca, L; Philip, S | 1 |
| Abu-Rashid, M; Chai, P; Davidson, M; Nilsson, C; Offman, E | 1 |
| Sarris, J | 1 |
| Brinton, EA; Mason, RP | 1 |
| Daak, A; Freedman, SD; Harris, WS; Johns, C; Maki, KC; Puder, M; Rabinowicz, AL; Sancilio, FD; Thorsteinsson, T | 1 |
| Ballantyne, CM; Bhatt, DL; Braeckman, RA; Brinton, EA; Doyle, RT; Jacobson, TA; Juliano, RA; Ketchum, SB; Miller, M; Murphy, SA; Soni, PN; Steg, PG; Tardif, JC | 1 |
| Ashcroft, SP; Bell, G; Dick, J; Doherty, MK; Gallagher, I; Galloway, SDR; Hamilton, DL; Jeromson, S; Mackenzie, I; Philp, A; Rao, FV; Shaw, A; Whitfield, PD | 1 |
| Han, H; Liu, F; Long, B; Mei, Y; Qiao, Y; Shao, Y; Xie, B; Yang, XM | 1 |
| Alashmali, SM; Bazinet, RP; Kitson, AP; Lacombe, RJS; Lin, L | 1 |
| Le, V; Mason, RP; Nelson, JR; True, WS | 1 |
| Bentsen, H; Landrø, NI | 1 |
| Kloas, W; Krüger, A; Overton, JL; Schaefer, FJ; Wuertz, S | 1 |
| Copple, T; Gutstein, AS | 1 |
| Chen, GC; Eggersdorfer, M; Hidayat, K; Qin, LQ; Yang, J; Zhang, W; Zhang, Z | 1 |
| Brent Muhlestein, J; Budoff, M; Le, VT; May, HT; Nelson, JR; Roy, S | 1 |
| Fujii, M; Kawaguchi, N; Matsuda, H; Miyamoto, Y; Nabe, T; Ohya, S; Ohyanagi, C | 1 |
| Assies, J; Mocking, RJT; Ruhé, HG; Schene, AH | 1 |
| Argaw, A; Belachew, T; Bouckaert, KP; De Meulenaer, B; Huybregts, L; Kolsteren, P; Lachat, C; Wondafrash, M | 1 |
| Ballantyne, CM; Brinton, EA; Doyle, RT; Guyton, JR; Juliano, RA; Mosca, L; Philip, S | 1 |
| Stocks, J; Valdes, AM | 1 |
| Kasono, K; Nobe, K; Ohtake, K; Takenouchi, Y | 1 |
| Chen, HE; Hsu, MC; Tung, CY | 1 |
| Berger, EA; Carion, TW; Ebrahim, AS; Greenwood, M; Gronert, K; Jerome, A; Suvas, S | 1 |
| Fu, J; Gao, B; Xia, S; Xiong, J; Zhang, C | 1 |
| Bergkvist, L; Larsson, SC; Leppert, J; Michaëlsson, K; Religa, D; Stilling, F; Wolk, A | 1 |
| Cohen, AS; Furtado, JD; Giovannucci, EL; Granstrøm, C; Gørtz, S; Halldorsson, TI; Langhoff-Roos, J; Lykke, JA; Nielsen, PH; Olsen, SF; Strøm, M; Thorne-Lyman, AL; Wohlfahrt, J; Zhou, W | 1 |
| Daniels, R; Famula, TR; Kelley, R; Levy, K; Mundell, P; Oberbauer, AM | 1 |
| Burgher-Kennedy, N; Conus, N; Kaur Datta, G; van den Berg, F | 1 |
| Cinelli, MA; Karchalla, LM; Lee, KSS; Scharmen, A; Woodman, J; Yang, J | 1 |
| Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M | 1 |
| Bao, Z; Dong, Q; Li, M; Ren, Q; Yang, Q; Yang, Y; Zhang, Z | 1 |
| Chen, S; Geng, L; Hu, X; Huang, H; Ji, X; Ren, L; Sun, X | 1 |
| Aisen, PS; Andrieu, S; Coley, N; Donohue, MC; Raman, R; Vellas, B | 1 |
| Abbaspourrad, A; Brenna, JT; Jiang, X; Lee, MC | 1 |
| González-Barriga, V; López-Arana, S; Rincón-Cervera, MÁ; Romero, J; Valenzuela, A; Valenzuela, R | 1 |
| Malau-Aduli, AEO; Malau-Aduli, BS; Nguyen, DV; Nguyen, QV; Nichols, PD; Van Le, H | 1 |
| Barnett, DA; Gagnon, KJ; Lefort, N; Poirier, SJ; Surette, ME | 1 |
| Allshouse, AA; Cho, KJ; Hohos, NM; Rudolph, MC; Skaznik-Wikiel, ME; Swindle, DC | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Doyle, RT; Granowitz, C; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Miller, M; Steg, PG; Tardif, JC | 1 |
| Hamaguchi, T; Hamazaki, K; Hayashida, M; Kobayashi, M; Nakaya, N; Ogawa, S; Okamura, H; Shirabe, S; Sone, T; Takeoka, A; Tayama, J; Yajima, J | 1 |
| Kastelein, JJP; Stroes, ESG | 1 |
| Cai, A; Deng, Z; Hong, Z; Peng, J; Song, T; Wei, H; Wu, Y; Xia, M; Xiong, J; Yang, Y; Zhou, Y | 1 |
| Lim, GB | 1 |
| Li, X; Liu, F; Qi, B; Qing, X; Sun, Q; Wang, C; Yu, M | 1 |
| Adelfi, MG; Amodeo, P; d'Ippolito, G; Ferrante, MI; Fontana, A; Gallo, C; Landi, S; Manzo, E; Nuzzo, G; Pagano, D; Picariello, G; Vitale, RM | 1 |
| Jensen, GL; Kris-Etherton, PM; Maddipati, KR; Norris, PC; Richter, CK; Riley, I; Serhan, CN; Skulas-Ray, AC | 1 |
| Liu, C; Pang, S; Sun, Y; Wang, H; Ye, D; Zhang, X; Zhu, Z | 1 |
| Li, HY; Liu, JS; Luo, SW; Luo, W; Wang, X; Yang, WD | 1 |
| Fukunaga, K; Hosomi, R; Kanda, S; Miyauchi, K; Nagao, T; Nishiyama, T; Takahashi, K; Tanizaki, T; Yoshida, M | 1 |
| Anzalone, A; Askow, A; Carbuhn, A; Gable, D; Gallop, A; Harris, W; Jennings, W; Johnson, P; Jones, L; Kirk, KM; McBeth, J; Moore, C; Oliver, JM; Rimer, E; Smith, A; Swearingen, L | 1 |
| D'Aragon, F; Hardy, G; Langlois, PL; Manzanares, W | 1 |
| Barata, C; Checa, A; Fuchs, D; Garreta-Lara, E; Lacorte, S; Tauler, R; Wheelock, CE | 1 |
| Chen, Z; Jiang, P; Li, T; Wu, H; Xiang, W; Xu, J | 1 |
| Fegan, PG; Lan, NSR; Rankin, JM; Watts, GF; Yeap, BB | 1 |
| Akeroyd, JM; Ballantyne, CM; Jia, X; Nambi, V; Nasir, K; Petersen, LA; Virani, SS | 1 |
| Chen, GY; Gillitt, ND; Nieman, DC; Sakaguchi, CA; Stephan, EH; Zhang, Q | 1 |
| Ahmed Hassan, HI; Anh Ngoc, CT; Dang, NP; Doheim, MF; Eisa, AA; El-Basiony, DSM; Hirayama, K; Huy, NT; Kamel, MG; Khalil, SM; Morsy, S | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Doyle, RT; Granowitz, C; Gregson, J; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Miller, M; Pocock, SJ; Steg, PG; Tardif, JC | 1 |
| Huynh, K | 1 |
| Drozd, A; Kaczkan, M; Maciejewska, D; Marczuk, N; Małgorzewicz, S; Owczarzak, A; Palma, J; Rutkowski, P; Szczuko, M | 1 |
| Katsiki, N; Mikhailidis, DP; Perez-Martinez, P | 1 |
| Bartlett, J; Ciesielski, TH; Williams, SM | 1 |
| Kanno, S; Obata, K; Osaka, S; Sekino, H; Sezai, A; Tanaka, M; Taoka, M; Unosawa, S | 1 |
| Chan, LN | 1 |
| Borghi, C; Cicero, AFG; Fogacci, F | 1 |
| Bhatt, DL; Miller, M; Steg, PG | 1 |
| Doggrell, SA | 1 |
| Carranza Martin, AC; Coleman, DN; Jin, Y; Lee, K; Relling, AE | 1 |
| Coleman, DN; Hamer, L; Nickles, KR; Relling, AE | 1 |
| Lee, M; Ovbiagele, B | 1 |
| Orringer, CE | 1 |
| Brigham, EP; Hansel, NN; Hanson, CK; Koch, A; Lemoine S, CM; McCormack, MC; Putcha, N; Woo, H | 1 |
| Al Rifai, M; Al-Mallah, MH; Jia, X; Martin, SS; Miedema, MD; Virani, SS | 1 |
| Haslam, A; Prasad, V | 1 |
| Gitin, A; Hennekens, CH | 1 |
| Bejaoui, S; Chalghaf, M; Chetoui, I; El Cafsi, M; Fouzai, C; Rabeh, I; Soudani, N; Telahigue, K; Trabelsi, W | 1 |
| Granger, CB; Nelson, AJ; Pagidipati, NJ | 1 |
| Ding, L; Han, XQ; Shi, HH; Wang, YM; Xue, CH; Zhang, LY; Zhang, TT | 1 |
| Huynh, K; Meikle, PJ; Mellett, NA; Sinclair, AJ; Smith, AT; Su, XQ; Sung, HH | 1 |
| Arumugam, M; Balakrishnan, J; Dhavamani, S; Ramalingam, J; Sadasivam, SG; Shanmugam, K; Vellaikumar, S | 1 |
| Battisha, A; Chilton, R; Hammad, T; Pham, S; Sheikh, O; Vande Hei, AG | 1 |
| Cui, Y; Schenk, PM; Thomas-Hall, SR | 1 |
| Ballantyne, CM; Bays, HE; Doyle, RT; Granowitz, C; Juliano, RA; Miller, M; Philip, S | 1 |
| Gao, L; Li, SC; Moodie, M | 1 |
| Cooper, TB; Gopaldas, M; Mann, JJ; Miller, JM; Ogden, RT; Oquendo, MA; Rubin-Falcone, H; Sublette, ME; Sullivan, G; Zanderigo, F; Zhan, S | 1 |
| Azlan, A; Loh, SP; Md Noor, S; Yakubu, A | 1 |
| Bailes, KL; Holman, BWB; Hopkins, DL; Kerr, MJ | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Gregson, J; Jacobson, TA; Jiao, L; Miller, M; Pocock, SJ; Steg, PG; Tardif, JC | 1 |
| Akita, H; Asukai, K; Kagawa, A; Marukawa, S; Miyata, H; Nishimura, J; Ochi, A; Ohue, M; Omori, T; Sakon, M; Soh, Y; Sugimura, K; Takahashi, H; Takahashi, Y; Taniguchi, Y; Tomokuni, A; Wada, H; Yamamoto, K; Yamasaki, T; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Barisic, A; Domislovic, V; Juretic, A; Kekez, D; Krznaric, Ž; Vranesic Bender, D | 1 |
| Bhatt, DL; Patel, PN; Patel, SM | 1 |
| Bolin, SR; Mazaki-Tovi, M; Schenck, PA | 1 |
| Burgess, VA; Calder, P; Cusack, R; Dushianthan, A; Grocott, MP | 1 |
| Miller, M | 1 |
| Azarnoush, K; Bonny, JM; Bouvier, D; Cassagnes, L; Demaison, L; Jouve, C; Leger, T; Pagès, G; Pereira, B; Rigaudière, JP; Sapin, V; Traoré, A | 1 |
| Hammer, SK; Olsvik, PA; Sanden, M; Søfteland, L | 1 |
| Dron, JS; Hegele, RA | 1 |
| Huang, X; Li, J; Li, Y; Zhang, J; Zhang, L; Zhao, L | 1 |
| Betancor, MB; Jiao, L; Jin, M; Sun, P; Tocher, DR; Wang, X; Yuan, Y; Zhou, Q | 1 |
| Tao, N; Wang, M; Wang, X; Zhang, J; Zhao, Y | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Budoff, MJ; Chung, MK; Doyle, RT; Gibson, CM; Giugliano, RP; Granowitz, C; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Miller, M; Olshansky, B; Steg, PG; Tardif, JC | 1 |
| Abelak, KK; Bishop-Bailey, D; Nobeli, I | 1 |
| Antequera, T; Perez-Palacios, T; Solomando, JC | 1 |
| Bhatt, DL; Boden, WE; Chapman, MJ; Lüscher, TF; Ray, KK; Toth, PP | 1 |
| Castiglioni, S; Cazzola, R; Cestaro, B; Della Porta, M; Maier, JAM; Pinotti, L | 1 |
| Medina, I; Méndez, L; Miralles-Pérez, B; Muñoz, S; Nogués, MR; Ramos-Romero, S; Torres, JL | 1 |
| Ding, L; Shi, H; Wang, C; Wang, Y; Xue, C; Zhang, L; Zhang, T | 1 |
| Blumenthal, RS; Gulati, M; Mahtta, D; Mehta, A; Sperling, LS; Virani, SS | 1 |
| McDaniel, JC; Rausch, J; Tan, A | 1 |
| Cao, X; Fan, C; Wen, L | 1 |
| Avery, H; Calder, PC; Forster, J; Husberg, C; Hustvedt, SO; Jackson, PA; Kennedy, DO; Khan, J | 1 |
| Al Rifai, M; Blumenthal, RS; Jia, X; Koh, S; Virani, SS | 1 |
| Caballero-Solares, A; Eslamloo, K; Hall, JR; Parrish, CC; Rise, ML; Taylor, RG; Xue, X | 1 |
| Amano, T; Ando, H; Nakano, Y; Ohashi, H; Sakurai, S; Sawada, H; Shimoda, M; Suzuki, A; Takashima, H; Waseda, K | 1 |
| Peng, Z; Song, C; Wang, J; Yan, L; Yang, Z; Zhang, C; Zhang, Y | 1 |
| Spence, JD | 1 |
| Bandyopadhyay, D; Chatterjee, S; Deedwania, PC; Ghosh, RK; Hajra, A | 1 |
| Dixon, DL | 1 |
| Mosca, L; Navar, AM; Wenger, NK | 1 |
| Chen, H; Chen, W; Chen, YQ; Tang, X; Wang, S; Wang, Y; Zhang, H | 1 |
| Ding, L; Ji, S; Li, L; Xia, Y; Zhao, S | 1 |
| Arnwine, C; Lockwood, K; Magness, JW; Reinert, A | 1 |
| Campbell, JD; McQueen, RB; Ollendorf, DA; Pearson, SD; Synnott, PG | 1 |
| Ballantyne, CM; Hussain, A; Saeed, A; Virani, SS | 1 |
| Ganda, OP | 1 |
| Agarwala, A; Al Rifai, M; Gulati, M; Jia, X; Liu, J; Virani, SS | 1 |
| Lee-Rangel, HA; Oviedo-Ojeda, MF; Relling, AE; Roque-Jimenez, JA; Whalin, M | 1 |
| Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le Pa, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J | 1 |
| Chen, SY; Chen, WT; Lee, CC; Lee, TM; Wu, DW | 1 |
| Krennhuber, K; Möderndorfer, B; Nedbalová, L; Nicoletti, C; Procházková, L; Remias, D | 1 |
| Bhatt, DL; Curfman, G; Pencina, M | 1 |
| Le, V; Nelson, JR; Trivedi, K | 1 |
| Bazarbashi, N; Miller, M | 1 |
| Bhatt, DL; Budoff, MJ; Kinninger, A; Lakshmanan, S; Le, VT; May, HT; Muhlestein, JB; Nelson, JR; Roy, SK; Shaikh, K; Shekar, C; Tayek, J | 1 |
| Bhatt, DL; Kosmopoulos, A; Mazer, CD; Meglis, G; Verma, R; Verma, S; Voisine, P | 1 |
| Fan, W; Granowitz, C; Philip, S; Toth, PP; Wong, ND | 1 |
| Baum, S; Bhatt, DL; Boden, WE; Fazio, S; Toth, PP | 1 |
| Antebi, A; Chamoli, M; Goyala, A; Lithgow, GJ; Mukhopadhyay, A; Siddiqui, AA; Singh, A; Tabrez, SS; Watts, JL | 1 |
| Abosheasha, MA; El-Gowily, AH | 1 |
| Agarwala, A; Al Rifai, M; Hussain, A; Jia, X; Martin, S; Virani, SS | 1 |
| Araujo de Carvalho, I; Beard, J; Cantet, C; de Souto Barreto, P; Giudici, KV; Rolland, Y; Vellas, B | 1 |
| Cuspidi, C; Tadic, M | 1 |
| Bhatt, DL; Mason, RP; Verma, S; Wang, X | 1 |
| Catapano, AL; Tokgozoglu, L | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Budoff, MJ; Doyle, RT; Gibson, CM; Giugliano, RP; Granowitz, C; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Miller, M; Peterson, BE; Pinto, D; Steg, PG; Tardif, JC; Verma, S | 2 |
| Chang, CC; Chang, CH; Chiang, CF; Huang, YC; Liao, JW; Lin, HT; Ni, SP; Yen, GC | 1 |
| Eskander, JP; Hall, W; Kaye, AD; Patel, H; Suh, W; Urits, I; Viswanath, O | 1 |
| Balvers, M; Bosi, R; Diepeveen-de Bruin, M; Headley, L; Manusama, K; Schwarm, M; Witkamp, R | 1 |
| Myran, L; Nguyen, TN | 1 |
| Aboalhasan, E; Arbel, R; Azuri, J; Hammerman, A | 1 |
| Fu, Y; Gao, H; Ge, L; Jiang, R; Li, D; Tong, C; Wang, Y; Xu, K | 1 |
| Aparicio, E; Arija, V; Basora, J; Bedmar, C; Martín-Grau, C; Serrat Orus, NS | 1 |
| Ambrosy, AP; Avula, HR; Bhatt, DL; Fitzpatrick, JK; Go, AS; Goh, CH; Granowitz, C; Malik, UI; Parikh, RV; Philip, S; Selby, VN; Skarbinski, J; Solomon, MD; Tan, TC; Thomas, RC | 1 |
| Ito, H; Kishinoue, T; Matsuo, N; Miyoshi, T; Nakano, Y; Onishi, N; Takaishi, A; Tanimoto, M; Ueeda, M; Yasuhara, K | 1 |
| Barlow, CE; Cooper, KH; DeFina, LF; Farrell, SW; Harris, WS; Haskell, WL; Leonard, D; Pavlovic, A; Tintle, NL | 1 |
| Bazinet, RP; Serhan, CN; Simopoulos, AP | 1 |
| Hamazaki, K; Matsuoka, YJ; Mimura, M; Nozaki, S; Sawada, N; Shikimoto, R; Tsugane, S; Yamaji, T | 1 |
| Anderson, TJ; Barry, AR; Couture, P; Dayan, N; Francis, GA; Genest, J; Grégoire, J; Grover, SA; Gupta, M; Hegele, RA; Lau, D; Leiter, LA; Leung, AA; Lonn, E; Mancini, GBJ; Manjoo, P; McPherson, R; Ngui, D; Pearson, GJ; Piché, ME; Poirier, P; Sievenpiper, J; Stone, J; Thanassoulis, G; Ward, R; Wray, W | 1 |
| Anderson-Berry, A; Hanson, C; Harris Jackson, K; Mukherjee, M; Natarajan, SK; Nordgren, TM; Thoene, M; Thompson, M; Ulu, A; Van Ormer, M; Woodard, V; Yuil-Valdes, A | 1 |
| Eckel, RH; Mason, RP | 1 |
| Ding, L; Li, Q; Mao, XZ; Shi, HH; Wang, YM; Xu, ZJ; Xue, CH; Zhang, TT | 1 |
| Curfman, G; Shehada, E | 1 |
| Budoff, MJ; Le, V; Nelson, A; Nelson, JR; Nemiroff, RL; Patel, DK; Wani, OR | 1 |
| Cheng, AYY; Gilbert, JD; Goldenberg, RM; Lonn, EM; Pedersen, SD; Verma, S | 1 |
| Bhatt, DL; Budoff, M; Lakshmanan, S | 1 |
| Garcia-Garcia, HM; Rodriguez-Granillo, GA | 1 |
| Lee, M; Ovbiagele, B; Saver, JL | 1 |
| Ding, L; Du, L; Shi, HH; Wang, CC; Wang, YM; Xue, CH; Yanagita, T; Zhang, TT | 1 |
| Bhatt, DL; Mason, RP; Pareek, M | 1 |
| Lloyd-Jones, DM; Wilkins, JT | 2 |
| Ademi, Z; Liew, D; Ofori-Asenso, R; Owen, A; Zomer, E | 1 |
| Bedu-Addo, K; Bovet, P; Choo-Kang, C; Forrester, T; Korte, W; Lambert, EV; Luke, A; Mehta, S; Plange-Rhule, J; Riesen, W; Ruth Dugas, L | 1 |
| Chang, WC; Lamon-Fava, S; So, J | 1 |
| Bhatt, DL; Ducrocq, G; Eagle, KA; Elbez, Y; Goto, S; Ohman, EM; Picard, F; Smith, SC; Steg, PG; Wilson, PWF | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Budoff, MJ; Doyle, RT; Gaba, P; Gibson, CM; Giugliano, RP; Granowitz, C; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Miller, M; Pinto, DS; Steg, PG; Tardif, JC | 1 |
| Doi, T; Langsted, A; Nordestgaard, BG | 1 |
| Bhatt, DL; Steg, PG | 1 |
| Armstrong, M; Manke, J; Quinn, K; Reisdorph, N; Shaikh, SR; Vander Ploeg, M | 1 |
| Ali, US; Bell, DA; Dwivedi, G; Lan, NSR; Larbalestier, R | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Jacobson, TA; Jiao, L; Mason, RP; Miller, M; Singh, N; Steg, PG; Tardif, JC | 1 |
| Ballantyne, CM; Bays, HE; Ferguson, JJ; Johnson, JB; Kastelein, JJP; Maki, KC; Underberg, JA | 1 |
| Chapman, MJ; Parhofer, KG; Zamorano, JL | 1 |
| Babalola, F; Bulic, A; Curtis, J; Ng, D | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Doyle, RT; Gaba, P; Gibson, CM; Giugliano, RP; Granowitz, C; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Martens, FMAC; Miller, M; Steg, PG; Tardif, JC | 1 |
| Andersson, C; Boden, WE | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Glynn, RJ; Jacobson, TA; Jiao, L; MacFadyen, J; Mason, RP; Miller, M; Ridker, PM; Rifai, N; Steg, PG; Tardif, JC | 1 |
| Chen, H; Chen, W; Li, H; Li, J; Li, X; Li, Y; Liu, C; Sheng, L; Xu, H; Yang, M; Yuan, F | 1 |
| Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T | 1 |
| Brinton, EA; Catapano, AL; Handelsman, Y; Landmesser, U; Leiter, LA; Miller, M; Parhofer, KG; Tokgozoglu, L | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Budoff, M; Jacobson, TA; Jiao, L; Mason, RP; Miller, M; Steg, PG; Tardif, JC | 1 |
| Ademi, Z; Liew, D; Morton, JI; Nicholls, SJ | 1 |
| Mori, T; Murasaki, K; Yokoyama, Y | 1 |
| Arrieta, F; Barrios, V; Escobar, C; Gámez, JM; Gimeno-Orna, JA; Gómez-Doblas, JJ; Pedro-Botet, J; Pérez, A; Sánchez-Margalet, V; Tamargo, J | 1 |
| Abbas, NAT; Abdelsameea, AA; Alabassery, N; Alsemeh, AE; Fawzy, A; Samy, W | 1 |
| Bhatt, DL; Cannon, CP; Cater, NB; Cherney, DZI; Cosentino, F; Dagogo-Jack, S; Frederich, R; Kim, JM; Liu, CC; Mancuso, JP; McGuire, DK; Pratley, RE | 1 |
| Jin, Q; Karrar, E; Wang, X; Wu, G; Yi, M; You, Y; Zhang, H; Zhang, L; Zhang, Y | 1 |
| Hashimoto, M; Matsuura, T; Sugahara, K; Tsuda, J; Yamamoto, Y; Yamashita, H | 1 |
| Ballantyne, CM; Bhatt, DL; Brinton, EA; Chung, MK; Doyle, RT; Jacobson, TA; Jiao, L; Juliano, RA; Ketchum, SB; Kowey, PR; Miller, M; Olshansky, B; Reiffel, JA; Steg, PG; Tardif, JC | 1 |
| Bernelli, C; Biscaglia, S; Casella, M; Scala, A | 1 |
| Ashchi, M; Berner, J; Bisharat, M; Cox, A; Goldfaden, R; Gore, A; Huston, J; Jones, T; Langley, L; Lor, P; Mcgee, S; Schaffner, H; Sheikh-Ali, M; Skrable, B; Sperry, A; Sutton, D | 1 |
| Bäck, M | 1 |
| Chen, X; Chen, Y; Ge, J; He, L; Jiang, S; Lai, C; Li, Z; Liu, F; Liu, P; Liu, S; Man, R; Qi, X; Qiu, Z; Qu, Y; Shang, Y; Wang, Z; Wu, L; Xu, C; Zhang, S; Zhang, X | 1 |
| Di Costanzo, A; Esposito, G; Indolfi, C; Sorrentino, S; Spaccarotella, CAM | 1 |
58 review(s) available for eicosapentaenoic acid ethyl ester and eicosapentaenoic acid
| Article | Year |
|---|---|
[Eicosapentaenoic acid].
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Clinical Trials as Topic; DNA-Binding Proteins; Eicosapentaenoic Acid; Humans; Hyperlipidemias; Lipid Metabolism; Liver; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E).
Topics: Animals; Eicosapentaenoic Acid; Humans; Lipids; Mental Disorders; Psychotropic Drugs; Technology, Pharmaceutical | 2002 |
Ethyl-eicosapentaenoate and dexamethasone resistance in therapy-refractory depression.
Topics: Animals; Antidepressive Agents; CD4-CD8 Ratio; Depressive Disorder, Major; Dexamethasone; Drug Resistance; Eicosapentaenoic Acid; Humans; Hypothalamo-Hypophyseal System; Immune System; Leukocyte Count; Pituitary-Adrenal System; Psychiatric Status Rating Scales | 2004 |
Bioactive lipids in schizophrenia.
Topics: Antipsychotic Agents; Arachidonic Acid; Brain; Clinical Trials as Topic; Drug Therapy, Combination; Eicosapentaenoic Acid; Humans; Membrane Lipids; Neuronal Plasticity; Neurons; Neurotransmitter Agents; Phospholipases A; Phospholipases A2; Schizophrenia; Synaptic Membranes; Synaptic Transmission | 2006 |
Ethyl-EPA in Huntington disease: potentially relevant mechanism of action.
Topics: Animals; Brain; Clinical Trials as Topic; Eicosapentaenoic Acid; Humans; Huntington Disease | 2007 |
Isosapent ethyl (Vascepa) for severe hypertriglyceridemia.
Topics: Animals; Clinical Trials as Topic; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Severity of Illness Index; Triglycerides | 2013 |
Icosapent ethyl for treatment of elevated triglyceride levels.
Topics: Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2013 |
Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.
Topics: Antidepressive Agents; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Eicosapentaenoic Acid; Ginkgo biloba; Humans; Plant Preparations; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Platelet Aggregation Inhibitors | 2014 |
Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Topics: Cholesterol, LDL; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents | 2014 |
Icosapent ethyl: a review of its use in severe hypertriglyceridemia.
Topics: Administration, Oral; Adult; Animals; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Severity of Illness Index; Triglycerides | 2014 |
Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?
Topics: Biomarkers; Cardiovascular Diseases; Down-Regulation; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Risk Factors; Treatment Outcome; Triglycerides | 2015 |
Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Cholesterol, LDL; Diet; Dietary Supplements; Docosahexaenoic Acids; Dyslipidemias; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Prescription Drugs | 2016 |
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Topics: Adult; Biological Availability; Cholesterol, LDL; Diacylglycerol O-Acyltransferase; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Esters; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipogenesis; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Oxidation-Reduction; Triglycerides | 2016 |
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Topics: Dietary Supplements; Drug Prescriptions; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans | 2017 |
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaque, Atherosclerotic; Risk Factors; Triglycerides | 2017 |
Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
Topics: Cardiovascular Diseases; Dietary Supplements; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils; Humans; Hypertriglyceridemia; Prescription Drugs; Risk Factors; Triglycerides | 2017 |
Effect of omega-3 long-chain polyunsaturated fatty acid supplementation on heart rate: a meta-analysis of randomized controlled trials.
Topics: Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Heart Rate; Humans; Randomized Controlled Trials as Topic | 2018 |
Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders.
Topics: Eicosapentaenoic Acid; Fatty Acids; Humans; Hypothalamo-Hypophyseal System; Inflammation; Mental Disorders; Metabolism, Inborn Errors; Oxidative Stress; Pituitary-Adrenal System | 2018 |
Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation.
Topics: Adult; Clinical Trials as Topic; Depression; Depression, Postpartum; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Pregnancy; Pregnancy Complications | 2018 |
Omega-3 polyunsaturated fatty acids in critically ill patients with acute respiratory distress syndrome: A systematic review and meta-analysis.
Topics: Antioxidants; Critical Illness; Eicosapentaenoic Acid; Enteral Nutrition; Fatty Acids, Omega-3; gamma-Linolenic Acid; Humans; Immunomodulation; Length of Stay; Randomized Controlled Trials as Topic; Respiration, Artificial; Respiratory Distress Syndrome; Treatment Outcome | 2019 |
Efficacy of ethyl-EPA as a treatment for Huntington disease: a systematic review and meta-analysis.
Topics: Eicosapentaenoic Acid; Humans; Huntington Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
The Role of n-3 Fatty Acids in Cardiovascular Disease: Back to the Future.
Topics: Biomarkers; Cardiovascular Diseases; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Humans; Lipids; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2020 |
Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Triglycerides | 2019 |
Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?
Topics: Adult; Aged; Atherosclerosis; Biomarkers; Clinical Decision-Making; Consensus; Dyslipidemias; Eicosapentaenoic Acid; Evidence-Based Medicine; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Young Adult | 2020 |
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dicarboxylic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United States | 2019 |
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial.
Topics: Atrial Fibrillation; Biomarkers; Cardiovascular Diseases; Dietary Supplements; Down-Regulation; Eicosapentaenoic Acid; Female; Hemorrhage; Humans; Hypertriglyceridemia; Incidence; Male; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Triglycerides | 2019 |
Phaeodactylum tricornutum microalgae as a rich source of omega-3 oil: Progress in lipid induction techniques towards industry adoption.
Topics: Carbon Dioxide; Diatoms; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Food Industry; Hydrogen-Ion Concentration; Lipids | 2019 |
Can Yellow Stripe Scad Compete with Salmon on Its Role in Platelet Phospholipid Membrane and Its Cardiovascular Benefits?
Topics: Adult; Animals; Anti-Inflammatory Agents; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Fish Oils; Fishes; Humans; Hypercholesterolemia; Inflammation; Malaysia; Male; Phospholipids; Prospective Studies; Species Specificity | 2019 |
Cardiovascular risk reduction with icosapent ethyl.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Randomized Controlled Trials as Topic; Risk Factors; Risk Reduction Behavior; Triglycerides | 2019 |
Immunonutrition for Adults With ARDS: Results From a Cochrane Systematic Review and Meta-Analysis.
Topics: Antioxidants; Cause of Death; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Enteral Nutrition; Fatty Acids, Omega-3; gamma-Linolenic Acid; Humans; Randomized Controlled Trials as Topic; Respiration, Artificial; Respiratory Distress Syndrome | 2020 |
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Triglycerides | 2020 |
Cardiovascular Disease Prevention in Focus: Highlights from the 2019 American Heart Association Scientific Sessions.
Topics: American Heart Association; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Colchicine; Eicosapentaenoic Acid; Humans; Interleukin-6; Mutation; Myocardial Infarction; PCSK9 Inhibitors; Receptors, Interleukin-6; Risk Factors; United States | 2020 |
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date.
Topics: Animals; Cardiovascular Diseases; Dietary Supplements; Eicosapentaenoic Acid; Evidence-Based Medicine; Humans; Protective Factors; Risk Assessment; Risk Factors | 2020 |
Defining the Role of Icosapent Ethyl in Clinical Practice.
Topics: Drug Dosage Calculations; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Randomized Controlled Trials as Topic; Risk Factors | 2020 |
Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
Topics: Biomarkers; Cardiovascular Diseases; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Lipid Regulating Agents; Risk Factors | 2020 |
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Eicosapentaenoic Acid; Hemorrhage; Humans; Models, Economic; Randomized Controlled Trials as Topic; Rivaroxaban; Time Factors; Treatment Outcome | 2020 |
Triglycerides and ASCVD Risk Reduction: Recent Insights and Future Directions.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Apolipoprotein C-III; Atherosclerosis; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipid Regulating Agents; Lipoproteins; Male; Middle Aged; Polymorphism, Single Nucleotide; Risk Reduction Behavior; RNA Interference; Triglycerides | 2020 |
When to lower triglycerides?
Topics: Animals; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Triglycerides | 2020 |
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Child; Cholesterol, LDL; Denervation; Eicosapentaenoic Acid; Electronic Nicotine Delivery Systems; Female; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hyperlipoproteinemia Type II; Hypertension; Kidney; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Smoking Cessation; United States; Young Adult | 2020 |
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Cost-Benefit Analysis; Cytokines; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Practice Guidelines as Topic; Risk Factors; United States; United States Food and Drug Administration | 2021 |
Icosapent Ethyl: Niche Drug or for the Masses?
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Pharmaceutical Preparations; Risk Factors; Triglycerides | 2020 |
Generalizability of Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial in patients with a history of coronary artery bypass graft surgery.
Topics: Canada; Cardiovascular Diseases; Coronary Artery Bypass; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2021 |
Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well.
Topics: Benzhydryl Compounds; Betacoronavirus; Cardiology; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Congresses as Topic; Coronavirus Infections; COVID-19; Eicosapentaenoic Acid; Europe; Glucosides; Humans; Lipid Regulating Agents; Oligonucleotides; Pandemics; Pneumonia, Viral; SARS-CoV-2; Societies, Medical; Telecommunications | 2020 |
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Heart Disease Risk Factors; Humans; Risk Factors | 2020 |
Associations among Dietary Omega-3 Polyunsaturated Fatty Acids, the Gut Microbiota, and Intestinal Immunity.
Topics: Animals; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Gastrointestinal Microbiome; Humans; Intestines | 2021 |
Association of the Omega-3 Index with Incident Prostate Cancer with Updated Meta-Analysis: The Cooper Center Longitudinal Study.
Topics: Adult; Aged; Aged, 80 and over; Animals; Biomarkers; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Erythrocytes; Fatty Acids, Omega-3; Fish Oils; Fishes; Humans; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms | 2021 |
Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Risk Adjustment | 2021 |
Icosapent ethyl: scientific and legal controversies.
Topics: Biomedical Research; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Lipid Regulating Agents; Secondary Prevention | 2021 |
EPA's pleiotropic mechanisms of action: a narrative review.
Topics: Anti-Inflammatory Agents; Atherosclerosis; Eicosapentaenoic Acid; Humans; Lipid Regulating Agents; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Treatment Outcome | 2021 |
The role of icosapent ethyl in cardiovascular risk reduction.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Risk Factors; Triglycerides | 2021 |
Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides.
Topics: Adult; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertriglyceridemia; Lipid Regulating Agents | 2022 |
Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins; Middle Aged; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2022 |
Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
Topics: Cardiovascular Diseases; Cholesterol; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Risk Factors; Societies, Medical; Triglycerides | 2022 |
Highly Valuable Fish Oil: Formation Process, Enrichment, Subsequent Utilization, and Storage of Eicosapentaenoic Acid Ethyl Esters.
Topics: Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fish Oils; Heart Diseases; Humans | 2023 |
A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Risk Factors; Triglycerides | 2023 |
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis.
Topics: Atherosclerosis; Eicosapentaenoic Acid; Humans; Inflammation | 2023 |
The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Ezetimibe; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; PCSK9 Inhibitors; Proprotein Convertase 9; Triglycerides | 2023 |
87 trial(s) available for eicosapentaenoic acid ethyl ester and eicosapentaenoic acid
| Article | Year |
|---|---|
Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester.
Topics: Aged; Albuminuria; Body Weight; Diabetic Nephropathies; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged | 1990 |
[Effects of 4 weeks' intake of polyunsaturated fatty acid ethylester rich in eicosapentaenoic acid (ethylester) on plasma lipids, plasma and platelet phospholipid fatty acid composition and platelet aggregation; a double blind study].
Topics: Adult; Blood Platelets; Clinical Trials as Topic; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Lipids; Male; Middle Aged; Phospholipids; Platelet Aggregation | 1983 |
Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients.
Topics: Acetylglucosaminidase; Administration, Oral; Aged; Albuminuria; Analysis of Variance; beta 2-Microglobulin; Biomarkers; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eicosapentaenoic Acid; Female; Humans; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors | 1995 |
[Effect of supplementation with eicosapentaenoic acid ethyl ester, MND-21, on generation of leukotrienes by calcium ionophore-activated leukocytes in bronchial asthma].
Topics: Aged; Asthma; Calcimycin; Cells, Cultured; Eicosapentaenoic Acid; Female; Humans; Leukocytes; Leukotrienes; Male; Middle Aged | 1995 |
[Changes in platelet count and mean volume of platelet after administration of icosapentaenoic acid ethyl-ester, and factors that may affect those changes].
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Blood Platelets; Cell Size; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Thrombosis | 1994 |
Effects of low-dose EPA-E on glycemic control, lipid profile, lipoprotein(a), platelet aggregation, viscosity, and platelet and vessel wall interaction in NIDDM.
Topics: Adenosine Diphosphate; Analysis of Variance; Blood Glucose; Blood Platelets; Blood Viscosity; Collagen; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eicosapentaenoic Acid; Endothelium, Vascular; Erythrocyte Deformability; Extracellular Matrix; Female; Humans; In Vitro Techniques; Lipoprotein(a); Male; Middle Aged; Platelet Activating Factor; Platelet Adhesiveness; Platelet Aggregation | 1993 |
Impact of polyunsaturated fatty acids on human colonic bacterial metabolism: an in vitro and in vivo study.
Topics: Adult; Bacteroides; Breath Tests; Colon; Eicosapentaenoic Acid; Escherichia coli; Fatty Acids, Unsaturated; Female; Humans; In Vitro Techniques; Male; Platelet Aggregation Inhibitors | 1995 |
Increased plasma thrombin-antithrombin III complex levels in non-insulin dependent diabetic patients with albuminuria are reduced by ethyl icosapentatenoate.
Topics: Albuminuria; Antithrombin III; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Humans; Peptide Hydrolases; Platelet Aggregation Inhibitors | 1995 |
Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Time Factors; Triglycerides | 1998 |
Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients.
Topics: Administration, Oral; Adult; Aged; Arteriosclerosis; Drug Administration Schedule; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Female; Humans; Kidney Failure, Chronic; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Reference Values; Renal Dialysis; Treatment Outcome | 1999 |
Incorporation and washout of orally administered n-3 fatty acid ethyl esters in different plasma lipid fractions.
Topics: Adult; Analysis of Variance; Cholesterol Esters; Dietary Supplements; Docosahexaenoic Acids; Drug Administration Schedule; Eicosapentaenoic Acid; Female; Half-Life; Humans; Lipid Metabolism; Male; Phospholipids; Triglycerides | 1999 |
Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group.
Topics: Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Eicosapentaenoic Acid; Estriol; Female; Humans; Hyperlipidemias; Menopause; Middle Aged; Obesity; Prospective Studies; Triglycerides | 2000 |
Eicosapentaenoic acid ethyl ester supplementation in cachectic cancer patients and healthy subjects: effects on lipolysis and lipid oxidation.
Topics: Aged; Cachexia; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Lipid Peroxidation; Lipolysis; Male; Middle Aged; Neoplasms; Oleic Acid; Palmitic Acid; Time Factors; Weight Loss | 2000 |
A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Neurologic Examination; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2001 |
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Patient Selection; Placebos; Research Design; Secondary Prevention; Treatment Outcome | 2002 |
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment.
Topics: Aged; Atrophy; Brain; Double-Blind Method; Dyskinesia, Drug-Induced; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Huntington Disease; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Severity of Illness Index; Subtraction Technique | 2002 |
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Treatment Outcome | 2002 |
omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study.
Topics: Adult; Aggression; Borderline Personality Disorder; Depressive Disorder; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Follow-Up Studies; Humans; Pilot Projects; Psychiatric Status Rating Scales; Treatment Outcome | 2003 |
A pilot open case series of ethyl-EPA supplementation in the treatment of anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Male; Pilot Projects; Treatment Outcome | 2004 |
Ethyl-EPA in Alzheimer's disease--a pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Eicosapentaenoic Acid; Erythrocyte Membrane; Fatty Acids; Female; Humans; Male; Pilot Projects; Tomography, X-Ray Computed | 2004 |
Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Apoptosis; Brain; Cohort Studies; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Huntington Disease; Male; Middle Aged; Mitochondria; Movement; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidative Stress; Placebo Effect; Treatment Outcome | 2005 |
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome | 2006 |
Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brain; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Neuroprotective Agents; Organ Specificity | 2007 |
Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Male; Psychotic Disorders; Severity of Illness Index; Treatment Outcome | 2007 |
Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study.
Topics: Adolescent; Adult; Brain; Brain Chemistry; Brain Mapping; Dietary Supplements; Double-Blind Method; Eicosapentaenoic Acid; Female; Glutamic Acid; Glutamine; Glutathione; Humans; Magnetic Resonance Spectroscopy; Male; Oxidative Stress; Placebos; Psychotic Disorders; Temporal Lobe; Time Factors; Treatment Outcome; Up-Regulation | 2008 |
Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage?
Topics: Adult; Aged; Aged, 80 and over; Aneurysm, Ruptured; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Intracranial Aneurysm; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Subarachnoid Hemorrhage; Treatment Outcome; Vasospasm, Intracranial | 2008 |
Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects.
Topics: Adult; Blood Coagulation Tests; Blood Platelets; Docosahexaenoic Acids; Eicosapentaenoic Acid; Erythrocytes; Fatty Acids; Fatty Acids, Omega-3; Humans; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Thromboxane B2 | 2008 |
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study.
Topics: Adult; Analysis of Variance; Canada; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Huntington Disease; Male; Middle Aged; Neuropsychological Tests; Severity of Illness Index; Treatment Outcome; Trinucleotide Repeat Expansion; United States | 2008 |
Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Dietary Supplements; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Mental Health; Mental Status Schedule; Middle Aged; Placebos; Psychiatric Status Rating Scales; Severity of Illness Index; Stress, Psychological; Treatment Outcome | 2009 |
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder.
Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Lipids; Male; Middle Aged; Pilot Projects; Placebos; Platelet Aggregation Inhibitors; Psychiatric Status Rating Scales; Treatment Outcome | 2009 |
Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study.
Topics: Adolescent; Analysis of Variance; Double-Blind Method; Eicosapentaenoic Acid; Female; Hippocampus; Humans; Longitudinal Studies; Male; Neuroprotective Agents; Pilot Projects; Psychotic Disorders; Statistics as Topic; Young Adult | 2010 |
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capsules; Carotid Artery Diseases; Chi-Square Distribution; Cytokines; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Endarterectomy, Carotid; England; Female; Foam Cells; Gene Expression Regulation; Humans; Inflammation; Inflammation Mediators; Male; Matrix Metalloproteinases; Middle Aged; Phospholipids; Preoperative Care; RNA, Messenger; Rupture, Spontaneous; T-Lymphocytes; Treatment Outcome | 2010 |
Supplementation with eicosapentaenoic omega-3 fatty acid does not influence serum brain-derived neurotrophic factor in diabetes mellitus patients with major depression: a randomized controlled pilot study.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Dietary Supplements; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Pilot Projects; Severity of Illness Index | 2011 |
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
Topics: Body Mass Index; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Placebos; Treatment Outcome | 2011 |
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Topics: Cardiovascular Diseases; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome; Triglycerides | 2012 |
A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.
Topics: Adult; Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Treatment Outcome; Triglycerides | 2012 |
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Topics: Biomarkers; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Eicosapentaenoic Acid; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Time Factors; Treatment Outcome; Triglycerides | 2013 |
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.
Topics: Adult; Affect; Anxiety; Depression; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Female; Hot Flashes; Humans; Menopause; Middle Aged; Perimenopause; Placebos; Postmenopause; Sleep; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Yoga | 2014 |
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Ascorbic Acid; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Humans; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Vitamin E; Vitamins; Young Adult | 2013 |
Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
Topics: Adult; Anticoagulants; Cytochrome P-450 CYP2C9; Eicosapentaenoic Acid; Female; Healthy Volunteers; Humans; Male; Middle Aged; Warfarin; Young Adult | 2014 |
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Topics: Biopsy; Disease Progression; Double-Blind Method; Eicosapentaenoic Acid; Fatty Liver; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; North America; Prospective Studies; Severity of Illness Index; Time Factors; Treatment Failure | 2014 |
Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.
Topics: Administration, Oral; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Eicosapentaenoic Acid; Humans; Hypolipidemic Agents; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2014 |
The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids.
Topics: Biological Availability; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fasting; Fatty Acids, Omega-3; Female; Humans; Male; Young Adult | 2015 |
The NMatrix, a new method of presenting statistics, displays the characteristics of medicines with similar effects used in the treatment of lumbar spinal stenosis concisely and clearly, facilitating the selection of appropriate medications.
Topics: Aged; Aged, 80 and over; alpha-Cyclodextrins; Alprostadil; Decision Making; Eicosapentaenoic Acid; Epoprostenol; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Pain Measurement; Platelet Aggregation Inhibitors; Sciatica; Spinal Stenosis; Succinates; Treatment Outcome | 2015 |
Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.
Topics: Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Lipids; Metabolic Syndrome; Time Factors; Treatment Outcome | 2015 |
Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods.
Topics: Adolescent; Adult; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Hypolipidemic Agents; Male; Psychiatric Status Rating Scales; Schizophrenia; Secondary Prevention; Treatment Outcome | 2015 |
Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Topics: Adult; Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Huntington Disease; Male; Middle Aged; Outcome Assessment, Health Care | 2015 |
A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Dietary Supplements; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Follow-Up Studies; Humans; Male; Mental Status Schedule; Outcome Assessment, Health Care; Reproducibility of Results; Schizophrenia; Treatment Outcome; Young Adult | 2016 |
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Topics: Adult; Aged; Atherosclerosis; Cardiovascular Diseases; Cholesterol; Data Interpretation, Statistical; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Platelet Aggregation Inhibitors; Triglycerides | 2016 |
Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoprotein C-III; Apolipoproteins B; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Treatment Outcome; Triglycerides | 2017 |
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Cohort Studies; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Esters; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Female; Healthy Volunteers; Humans; Male; Middle Aged; Young Adult | 2017 |
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Topics: Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; France; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Quebec; Risk Factors; Time Factors; Treatment Outcome; United Kingdom; United States | 2017 |
Neurocognitive effects of an omega-3 fatty acid and vitamins E+C in schizophrenia: A randomised controlled trial.
Topics: Adult; Antipsychotic Agents; Ascorbic Acid; Attention; Eicosapentaenoic Acid; Executive Function; Fatty Acids, Omega-3; Female; Humans; Male; Mental Status and Dementia Tests; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Vitamin E; Young Adult | 2018 |
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Biomarkers; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Treatment Outcome; Triglycerides | 2018 |
Effects of n-3 long-chain PUFA supplementation to lactating mothers and their breastfed children on child growth and morbidity: a 2 × 2 factorial randomized controlled trial in rural Ethiopia.
Topics: Adult; Breast Feeding; C-Reactive Protein; Child Development; Child, Preschool; Diet; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Ethiopia; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Fish Oils; Follow-Up Studies; Growth Disorders; Hemoglobins; Humans; Infant; Lactation; Male; Morbidity; Mothers; Socioeconomic Factors; Treatment Outcome; Young Adult | 2018 |
Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins, VLDL; Male; Middle Aged; Platelet Aggregation Inhibitors; Treatment Outcome; Triglycerides | 2018 |
A randomized trial comparing omega-3 fatty acid plasma levels after ingestion of emulsified and non-emulsified cod liver oil formulations.
Topics: Adolescent; Adult; Cod Liver Oil; Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Young Adult | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Triglycerides | 2019 |
Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial.
Topics: Adult; Combined Modality Therapy; Depression; Depressive Disorder; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotherapy | 2019 |
Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation.
Topics: Administration, Intravenous; Adult; Chromatography, Liquid; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Endotoxins; Fatty Acids, Omega-3; Female; Healthy Volunteers; Humans; Inflammation; Lipid Metabolism; Male; Metabolome; Metabolomics; Research Design; Tandem Mass Spectrometry; Young Adult | 2018 |
The Omega-3 Index in National Collegiate Athletic Association Division I Collegiate Football Athletes.
Topics: Athletes; Cross-Sectional Studies; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Erythrocytes; Fatty Acids, Omega-3; Female; Football; Humans; Male; Retrospective Studies; Universities; Young Adult | 2019 |
Carbohydrate intake attenuates post-exercise plasma levels of cytochrome P450-generated oxylipins.
Topics: Adult; Arachidonic Acid; Beverages; Bicycling; Blood Glucose; Cross-Over Studies; Cytochrome P-450 Enzyme System; Dietary Carbohydrates; Docosahexaenoic Acids; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Female; Humans; Male; Middle Aged; Musa; Oxygen Consumption; Oxylipins; Plasma; Time Factors; Water; Young Adult | 2019 |
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Topics: Aged; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation Inhibitors; Recurrence; Risk Factors; Survival Rate | 2019 |
Long-Term Comparison of Ethyl Icosapentate vs. Omega-3-Acid Ethyl in Patients With Cardiovascular Disease and Hypertriglyceridemia (DEFAT Trial).
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Cardiovascular Surgical Procedures; Cholesterol, LDL; Cystatin C; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Lipoproteins, LDL; Longitudinal Studies; Male; Middle Aged | 2019 |
Differential plasma postprandial lipidomic responses to krill oil and fish oil supplementations in women: A randomized crossover study.
Topics: Adult; Animals; Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Euphausiacea; Female; Fish Oils; Humans; Lipidomics; Lipids; Postprandial Period | 2019 |
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study).
Topics: Adult; Aged; Apolipoprotein C-III; Atherosclerosis; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Prognosis; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States | 2019 |
The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study.
Topics: Aged; Chemoradiotherapy; Dietary Supplements; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Muscle, Skeletal; Nutritional Status; Nutritional Support; Pancreatic Neoplasms; Preoperative Care; Prospective Studies | 2019 |
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.
Topics: Aged; Cholesterol, LDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Risk Factors; Stroke; United States | 2020 |
Impact of omega-3 fatty acid oral therapy on healing of chronic venous leg ulcers in older adults: Study protocol for a randomized controlled single-center trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Case-Control Studies; Chronic Disease; Cytokines; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Leg Ulcer; Lipid Regulating Agents; Male; Middle Aged; Neutrophils; Placebos; Quality of Life; Varicose Ulcer; Wound Healing | 2020 |
Diurnal rhythm of plasma EPA and DHA in healthy adults.
Topics: Adult; Circadian Rhythm; Docosahexaenoic Acids; Eating; Eicosapentaenoic Acid; Female; Humans; Male; Sleep | 2020 |
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Regulating Agents; Male; Middle Aged; Multidetector Computed Tomography; Plaque, Atherosclerotic; Prospective Studies; Time Factors; Treatment Outcome; Triglycerides | 2021 |
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Topics: Aged; Coronary Artery Disease; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Triglycerides | 2020 |
Effect of long-term omega-3 supplementation and a lifestyle multidomain intervention on intrinsic capacity among community-dwelling older adults: Secondary analysis of a randomized, placebo-controlled trial (MAPT study).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Female; Geriatric Assessment; Hand Strength; Healthy Lifestyle; Humans; Independent Living; Life Style; Longitudinal Studies; Male; Range of Motion, Articular | 2020 |
Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Eicosapentaenoic Acid; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors | 2021 |
In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA.
Topics: Biological Availability; Cross-Over Studies; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Lysine | 2021 |
Maternal Factors Associated with Levels of Fatty Acids, Specifically n-3 PUFA during Pregnancy: ECLIPSES Study.
Topics: Adult; Age Factors; Docosahexaenoic Acids; Educational Status; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Humans; Life Style; Linear Models; Longitudinal Studies; Obesity; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Third; Prospective Studies; Seafood; Smoking; Spain | 2021 |
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE).
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; COVID-19; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Respiratory Tract Infections | 2021 |
Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registr
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Myocardial Infarction; Registries; Risk Factors | 2021 |
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Topics: Aged; Angina, Unstable; Eicosapentaenoic Acid; Endpoint Determination; Female; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Male; Myocardial Infarction; Myocardial Revascularization; Stroke | 2021 |
A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Topics: Adult; C-Reactive Protein; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Triglycerides | 2022 |
Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI.
Topics: Double-Blind Method; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Myocardial Infarction; Percutaneous Coronary Intervention; Risk Factors; Stroke; Treatment Outcome; Triglycerides | 2022 |
Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
Topics: Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Myocardial Infarction; Stroke | 2022 |
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Double-Blind Method; Eicosapentaenoic Acid; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Interleukin-1beta; Interleukin-6; Lipoprotein(a); Mineral Oil | 2022 |
Pharmacokinetics of Icosapent Ethyl: An Open-Label, Multiple Oral Dose, Parallel Design Study in Healthy Chinese Subjects.
Topics: Adult; East Asian People; Eicosapentaenoic Acid; Female; Healthy Volunteers; Humans; Hypertriglyceridemia; Male | 2023 |
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking.
Topics: Eicosapentaenoic Acid; Humans; Myocardial Infarction; Smoking; Tobacco Products | 2023 |
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
Topics: Atrial Fibrillation; Eicosapentaenoic Acid; Humans; Risk Factors; Stroke; Treatment Outcome | 2023 |
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China.
Topics: Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Treatment Outcome; Triglycerides | 2023 |
250 other study(ies) available for eicosapentaenoic acid ethyl ester and eicosapentaenoic acid
| Article | Year |
|---|---|
Effect of ingestion of eicosapentaenoic acid ethyl ester on carrageenan-induced colitis in guinea pigs.
Topics: Animals; Body Weight; Carrageenan; Cecal Diseases; Colitis; Dinoprostone; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Fatty Acids; Guinea Pigs; Leukotriene B4; Macrophages; Male; Occult Blood; Thromboxane B2; Ulcer | 1992 |
Changes in fatty acid composition in rat blood and organs after infusion of eicosapentaenoic acid ethyl ester.
Topics: Animals; Cholesterol; Cholesterol Esters; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Nonesterified; Heart; Infusions, Intravenous; Kidney; Liver; Lung; Male; Myocardium; Phospholipids; Rats; Rats, Wistar; Spleen; Triglycerides | 1992 |
Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia.
Topics: Adult; Aged; Capsules; Eicosapentaenoic Acid; Fatty Acids; Female; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged | 1992 |
Beneficial effects of eicosapentaenoic acid for diabetic patients with arteriosclerosis obliterans.
Topics: Aged; Arteriosclerosis Obliterans; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Eicosapentaenoic Acid; Female; Hemodynamics; Humans; Male | 1992 |
Chemical stability of ethyl icosapentate against autoxidation. I. Effect of temperature on oxidation kinetics.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Eicosapentaenoic Acid; Kinetics; Oxidation-Reduction; Peroxides; Temperature; Thermodynamics; Vitamin E | 1992 |
Effect of ingestion of eicosapentaenoic acid ethyl-ester on the scavenger activity for acetylated LDL and the production of platelet-derived growth factor in rat peritoneal macrophages.
Topics: Administration, Oral; Animals; Cholesterol Esters; Eicosapentaenoic Acid; Lipoproteins, LDL; Macrophages; Male; Peritoneal Cavity; Platelet-Derived Growth Factor; Rats; Rats, Inbred Strains | 1991 |
Fatty acids in human platelets and plasma. Fish oils decrease sensitivity toward N2 microbubbles.
Topics: Adult; Arachidonic Acid; Arachidonic Acids; Blood Platelets; Decompression Sickness; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fish Oils; Humans; In Vitro Techniques; Male; Nitrogen; Plasma; Platelet Aggregation; Thrombosis | 1991 |
Effects of EPA and DHA ethylesters on plasma fatty acids and on platelets, PMN and monocytes in healthy volunteers.
Topics: Administration, Oral; Adult; Blood Platelets; Collagen; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Humans; Leukocytes, Mononuclear; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Oxygen; Phospholipids; Platelet Aggregation; Superoxides; Thromboxane B2; Zymosan | 1991 |
Role of 5-lipoxygenase products of arachidonic acid in cell-to-cell interaction between macrophages and natural killer cells in rat spleen.
Topics: Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arachidonic Acids; Cell Communication; Eicosapentaenoic Acid; Killer Cells, Natural; Macrophages; Male; Rats; Rats, Inbred Strains; Spleen | 1991 |
Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil.
Topics: Adenosine Triphosphate; Adult; Bleeding Time; Blood Platelets; Cholesterol; Collagen; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids; Fibrinolytic Agents; Fish Oils; Humans; In Vitro Techniques; Male; Phospholipids; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Reference Values; Thromboxanes; Triglycerides | 1991 |
Ingestion of eicosapentaenoic acid-ethyl ester renders rabbit LDL less susceptible to Cu2(+)-catalyzed-oxidative modification.
Topics: Animals; Cholesterol, LDL; Copper; Dietary Fats; Eicosapentaenoic Acid; Kinetics; Lipid Peroxidation; Lipoproteins, LDL; Male; Rabbits; Reference Values; Triglycerides | 1991 |
High dose eicosapentaenoic acid ethyl ester: effects on lipids and neutrophil leukotriene production in normal volunteers.
Topics: Adult; Cholesterol; Eicosapentaenoic Acid; Erythrocyte Membrane; Fatty Acids; Humans; Leukotriene B4; Lipids; Male; Neutrophils; Triglycerides | 1990 |
Effect of oral ingestion of eicosapentaenoic acid-ethyl ester on natural killer cell activity in rat spleen cells.
Topics: Animals; Eicosapentaenoic Acid; Fatty Acids; Killer Cells, Natural; Leukotriene B4; Male; Rats; Rats, Inbred Strains; Spleen | 1989 |
Antihypertensive properties of linoleic acid and fish oil omega-3 fatty acids independent of the prostaglandin system.
Topics: Angiotensin II; Animals; Aorta, Thoracic; Blood Pressure; Eicosapentaenoic Acid; Fish Oils; Hypertension; Indomethacin; Linoleic Acids; Male; Muscle Contraction; Phenylephrine; Prostaglandins; Rats; Rats, Inbred Strains; Renin | 1989 |
Effect of eicosapentaenoic acid ethyl ester on proteinuria of streptozotocin-induced diabetes mellitus in rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids; Glycosuria; Kidney; Lipids; Male; Proteinuria; Rats; Rats, Inbred Strains; Streptozocin | 1989 |
Effects of highly purified eicosapentaenoic acid on plasma beta thromboglobulin level and vascular reactivity to angiotensin II.
Topics: Administration, Oral; Adult; Angiotensin Amide; beta-Thromboglobulin; Blood Coagulation; Blood Pressure; Blood Vessels; Cholesterol, HDL; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; Humans; Male; Platelet Aggregation; Platelet Count | 1987 |
Alleviation of murine autoimmune disease by dietary marine lipids.
Topics: Animals; Autoimmune Diseases; Dietary Fats, Unsaturated; Eicosapentaenoic Acid; Fatty Acids; Female; Fish Oils; Lupus Nephritis; Male; Mice; Mice, Inbred NZB | 1987 |
[The effects of eicosapentaenoic acid ethyl ester (EPA-E) on arterial thrombosis in rabbits and vascular lesions in rats].
Topics: Animals; Eicosapentaenoic Acid; Ellagic Acid; Gangrene; Laurates; Male; Rabbits; Rats; Rats, Inbred Strains; Thrombosis | 1988 |
[Pharmacological studies of eicosapentaenoic acid ethylester (EPA-E) on high cholesterol diet-fed rabbits].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Platelets; Cholesterol, Dietary; Disease Models, Animal; Eicosapentaenoic Acid; Lipids; Male; Rabbits | 1988 |
[Effects of ethyl eicosapentaenoate (EPA-E) and its metabolite on the drug and fatty acid metabolizing enzyme systems in rat liver].
Topics: Animals; Docosahexaenoic Acids; Eicosapentaenoic Acid; Male; Microbodies; Microsomes, Liver; Mitochondria, Liver; Rats; Rats, Inbred Strains | 1988 |
Metabolic disposition of ethyl eicosapentaenoate and its metabolites in rats and dogs.
Topics: Acyl Coenzyme A; Animals; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Docosahexaenoic Acids; Dogs; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Unsaturated; Lipid Metabolism; Lipoproteins; Male; Mitochondria, Liver; Rats; Rats, Inbred Strains; Tissue Distribution | 1988 |
Lipid composition of platelets from patients with atherosclerosis: effect of purified eicosapentaenoic acid ethyl ester administration.
Topics: Adult; Aged; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Blood Platelets; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Fatty Acids; Female; Humans; Lipids; Male; Middle Aged | 1988 |
Metabolism of ethyl eicosapentaenoate (EPA-E) in rats and effect of its metabolites on ellagic acid-induced thrombus formation in the stenosed femoral artery of rabbits.
Topics: Animals; Arterial Occlusive Diseases; Eicosapentaenoic Acid; Ellagic Acid; Femoral Artery; Male; Rabbits; Rats; Rats, Inbred Strains; Thrombosis | 1988 |
Dietary marine lipids after the course of autoimmune disease.
Topics: Animals; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Unsaturated; Fish Oils; Glomerulonephritis, IGA; Liver; Mice; Mice, Inbred Strains; Phospholipids; Reference Values; Spleen | 1988 |
Viscosities of some triglycerides and ethylester of fatty acids frequently found in cell membranes--a possible effect of viscosity of fatty acids in phospholipids on hemorheology.
Topics: Blood Viscosity; Eicosapentaenoic Acid; Fatty Acids; Membrane Fluidity; Membrane Lipids; Oils; Phospholipids; Plants; Triglycerides | 1985 |
Hypotensive effects of eicosapentaenoic acid (EPA) and its influence on eicosanoid metabolism in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Eicosanoic Acids; Eicosapentaenoic Acid; Hypertension; Rats; Rats, Inbred SHR; Rats, Inbred Strains | 1986 |
Effects of orally administered ethyl ester of eicosapentaenoic acid (EPA; C20:5, omega-3) on PGI2-like substance production by rat aorta.
Topics: 6-Ketoprostaglandin F1 alpha; Administration, Oral; Animals; Aorta, Thoracic; Arachidonic Acid; Arachidonic Acids; Eicosapentaenoic Acid; Epoprostenol; Fatty Acids; Fatty Acids, Unsaturated; Lipids; Male; Platelet Aggregation; Prostaglandins; Rats; Rats, Inbred Strains | 1982 |
Effect of ethyl icosapentate on urinary calcium excretion in calcium oxalate stone formers.
Topics: Adult; Aged; Calcium; Calcium Oxalate; Eicosapentaenoic Acid; Female; Humans; Magnesium; Male; Middle Aged; Prostaglandins; Urea; Uric Acid; Urinary Calculi | 1995 |
Antithrombotic activity of a symmetrical triglyceride with eicosapentaenoic acid and gamma-linolenic acid in guinea pig mesenteric microvasculature.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Eicosapentaenoic Acid; Fatty Acids; Fibrinolytic Agents; Fluorescein; Fluoresceins; gamma-Linolenic Acid; Guinea Pigs; Light; Lipids; Liver; Male; Mesenteric Vascular Occlusion; Mesentery; Molecular Structure; Photochemistry; Soybean Oil; Structure-Activity Relationship; Triglycerides; Venules | 1995 |
Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on the physical properties of arterial walls in high cholesterol diet-fed rabbits.
Topics: Administration, Oral; Animals; Aorta; Arteriosclerosis Obliterans; Cholesterol, Dietary; Disease Models, Animal; Eicosapentaenoic Acid; Femoral Artery; Lipids; Male; Rabbits | 1993 |
Chemical stability of ethyl icosapentate against autoxidation. II. Effect of photoirradiation on oxidation kinetics.
Topics: Chromatography, High Pressure Liquid; Eicosapentaenoic Acid; Kinetics; Light; Oxidation-Reduction; Peroxides; Platelet Aggregation Inhibitors; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Ultraviolet Rays | 1994 |
Effect of eicosapentaenoic acid ethyl ester on albuminuria in streptozotocin-induced diabetic rats.
Topics: 6-Ketoprostaglandin F1 alpha; Albuminuria; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Eating; Eicosapentaenoic Acid; Fatty Acids; Kidney; Lipids; Male; Organ Size; Rats; Rats, Wistar; Thromboxane B2; Weight Gain | 1994 |
Delaying effects of dietary eicosapentaenoic-docosahexaenoic acids on development of "fatty streaks" in hypercholesterolaemic rabbits. A morphological study by scanning electron microscopy.
Topics: Animals; Cholesterol; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelium, Vascular; Hypercholesterolemia; Microscopy, Electron, Scanning; Platelet Aggregation Inhibitors; Rabbits | 1993 |
Effects of purified dietary n-3 ethyl esters on murine T lymphocyte function.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Diet; Diglycerides; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Interleukin-1; Lipid Metabolism; Lymphocyte Activation; Mice; Mice, Inbred C57BL; T-Lymphocytes | 1993 |
[The effect on changes in serum lipids and factors that may affect those changes after administration of icosapentaenoic acid ethyl ester].
Topics: Adult; Aged; Aged, 80 and over; Apoproteins; Cholesterol; Cholesterol, LDL; Eicosapentaenoic Acid; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Triglycerides | 1993 |
Changes of n-3 and n-6 fatty acids in plasma and circulating cells of normal subjects, after prolonged administration of 20:5 (EPA) and 22:6 (DHA) ethyl esters and prolonged washout.
Topics: Adult; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Female; Humans; Male; Middle Aged; Reference Values | 1993 |
Purified dietary n-3 polyunsaturated fatty acids alter diacylglycerol mass and molecular species composition in concanavalin A-stimulated murine splenocytes.
Topics: Animals; Chromatography, High Pressure Liquid; Concanavalin A; Dietary Fats; Diglycerides; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Mice; Mice, Inbred C57BL; Signal Transduction; Spleen | 1993 |
Effect of eicosapentaenoic acid ethyl on urine albumin excretion in NIDDM.
Topics: Albuminuria; Capsules; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors | 1993 |
[The effect of various factors on changes in the levels of unsaturated fatty acid in plasma and serum lipids after administration of icosapentaenoic acid ethyl ester].
Topics: Adult; Aged; Aged, 80 and over; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Humans; Lipids; Male; Middle Aged | 1993 |
Effects of highly purified ethyl all-cis-5,8,11,14,17-icosapentaenoate (EPA-E) on rabbit platelets.
Topics: Animals; Blood Platelets; Eicosapentaenoic Acid; Fatty Acids; In Vitro Techniques; Male; Phospholipids; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Thromboxane A2 | 1993 |
Modification of spleen phospholipid fatty acid composition by dietary fish oil and by n-3 fatty acid ethyl esters.
Topics: Animals; Cattle; Chromatography, High Pressure Liquid; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fats; Fatty Acids; Fatty Acids, Omega-3; Female; Fish Oils; Mice; Mice, Inbred NZB; Phospholipids; Spleen | 1993 |
Suppression of autoimmune disease by dietary n-3 fatty acids.
Topics: Animals; Autoimmune Diseases; Cattle; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Drug Synergism; Eicosapentaenoic Acid; Fats; Fatty Acids, Omega-3; Female; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Mice; Mice, Inbred NZB; Proteinuria | 1993 |
Mechanism of the lipid-lowering effect of ethyl all-cis-5,8,11,14,17-icosapentaenoate.
Topics: Administration, Oral; Animals; Bile; Cholesterol; Eicosapentaenoic Acid; Hydroxymethylglutaryl CoA Reductases; Intestinal Absorption; Lipoproteins; Liver; Male; Metabolic Clearance Rate; Microsomes, Liver; Rats; Rats, Wistar | 1993 |
Ethyl all-cis-5,8,11,14,17-icosapentaenoate modifies the biochemical properties of rat very low-density lipoprotein.
Topics: Animals; Apolipoproteins; Chromatography, High Pressure Liquid; Eicosapentaenoic Acid; Fatty Acids; Lipase; Lipoprotein Lipase; Lipoproteins, VLDL; Male; Microsomes, Liver; Rats; Rats, Wistar; Triglycerides | 1993 |
[Effects of ethyl all-cis-5,8,11,14,17-icosapentaenoate on low density lipoprotein in rabbits].
Topics: Animals; Eicosapentaenoic Acid; Hyperlipidemias; Lipoproteins, LDL; Liver; Male; Mice; Platelet Aggregation Inhibitors; Rabbits | 1995 |
Thin-layer chromatography and high-performance liquid chromatography for the assay of fatty acid compositions of individual phospholipids in platelets from non-insulin-dependent diabetes mellitus patients: effect of eicosapentaenoic acid ethyl ester admin
Topics: Blood Platelets; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Fatty Acids; Humans; Phospholipids; Platelet Aggregation Inhibitors | 1996 |
The formation of diradylglycerol molecular species in murine peritoneal macrophages varies dose-dependently with dietary purified eicosapentaenoic and docosahexaenoic ethyl esters.
Topics: Animals; Cells, Cultured; Diet; Diglycerides; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL | 1996 |
Effect of purified eicosapentaenoate ethyl ester on fibrinolytic capacity in patients with stable coronary artery disease and lower extremity ischaemia.
Topics: Administration, Oral; Adult; Aged; Antigens; Arteriosclerosis Obliterans; Blood Cell Count; Blood Glucose; Coronary Disease; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Humans; Leg; Lipids; Male; Middle Aged; Plasminogen Inactivators; Platelet Aggregation Inhibitors; Tissue Plasminogen Activator | 1996 |
An experimental study on transcutaneous absorption of ethylesters of eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) in pigs.
Topics: Adipose Tissue; Administration, Oral; Animals; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Lipids; Male; Ointments; Skin Absorption; Swine; Tissue Distribution | 1996 |
Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells.
Topics: Calcium; Calmodulin; Cells, Cultured; Eicosapentaenoic Acid; Endothelium, Vascular; Fatty Acids, Unsaturated; Glucose; Humans; Nitric Oxide; Sorbitol; Sucrose; Sulfonamides; Umbilical Veins | 1997 |
[Blood rheological study in rats with fatty liver--with special reference to effects of ethyl icosapentate].
Topics: Animals; Eicosapentaenoic Acid; Fatty Acids; Fatty Liver; Liver; Liver Circulation; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Rheology | 1997 |
Dietary effect of a symmetrical triacylglycerol, 1,3-biseicosapentaenoyl-2-gamma-linolenoyl glycerol, on fatty acid composition of guinea pigs.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Blood Pressure; Body Weight; Cholesterol; Diet; Eicosapentaenoic Acid; Fatty Acid Desaturases; Fatty Acids; Guinea Pigs; Lipid Metabolism; Lipids; Liver; Male; Phospholipids; Soybean Oil; Triglycerides | 1997 |
Effects of highly purified eicosapentaenoic acid on vascular reactivity to angiotensin II and norepinephrine in pregnant rabbits.
Topics: Angiotensin II; Animals; Blood Pressure; Eicosapentaenoic Acid; Female; Infusions, Intravenous; Norepinephrine; Pregnancy; Pregnancy Outcome; Pregnancy, Animal; Rabbits; Vasomotor System | 1997 |
Effect of long-term administration of ethyl eicosapentate (EPA-E) on local cerebral blood flow and glucose utilization in stroke-prone spontaneously hypertensive rats (SHRSP).
Topics: Animals; Autoradiography; Blood Pressure; Brain; Cerebrovascular Circulation; Eicosapentaenoic Acid; Glucose; Heart Rate; Male; Platelet Aggregation Inhibitors; Rats; Rats, Inbred SHR | 1997 |
Effects of ethyl-all-cis-5,8,11,14,17-icosapentaenoate (EPA-E), pravastatin and their combination on serum lipids and intimal thickening of cuff-sheathed carotid artery in rabbits.
Topics: Animals; Anticholesteremic Agents; Carotid Arteries; Cholesterol; Drug Interactions; Eicosapentaenoic Acid; Lipids; Male; Phospholipids; Pravastatin; Rabbits; Triglycerides | 1997 |
Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus.
Topics: Animals; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Dietary Fats; Disease Models, Animal; Eicosapentaenoic Acid; Fatty Acids; Glucose Tolerance Test; Glucose Transporter Type 4; Insulin; Insulin Resistance; Lipids; Liver; Male; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Olive Oil; Pancreas; Plant Oils; Platelet Aggregation Inhibitors; Rats; RNA, Messenger; Safflower Oil; Weight Gain | 1997 |
[Preventive effects of eicosapentaenoic acid (EPA) on cholesterol gallstone formation in hamsters].
Topics: Animals; Bile; Cholelithiasis; Cholesterol; Cricetinae; Disease Models, Animal; Eicosapentaenoic Acid; Male | 1997 |
Effect of replacing a high linoleate oil with a low linoleate, high alpha-linolenate oil, as compared with supplementing EPA or DHA, on reducing lipid mediator production in rat polymorphonuclear leukocytes.
Topics: alpha-Linolenic Acid; Animals; Calcimycin; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Eicosanoids; Eicosapentaenoic Acid; Ionophores; Linoleic Acid; Male; Neutrophils; Phospholipids; Plant Oils; Platelet Activating Factor; Rats; Rats, Sprague-Dawley; Safflower Oil | 1998 |
Delayed administration of ethyl eicosapentate improves local cerebral blood flow and metabolism without affecting infarct volumes in the rat focal ischemic model.
Topics: Animals; Autoradiography; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circulation; Delayed-Action Preparations; Disease Models, Animal; Eicosapentaenoic Acid; Glucose; Male; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Regional Blood Flow | 1999 |
Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt-sensitive rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Carrier Proteins; Catecholamines; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Dietary Fats; Eating; Eicosapentaenoic Acid; Fatty Acids; Hypertension; Insulin; Insulin Resistance; Ion Channels; Lipids; Male; Membrane Proteins; Mitochondrial Proteins; Rats; Rats, Inbred Dahl; Sucrose; Uncoupling Protein 1 | 1999 |
Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation.
Topics: Action Potentials; Animals; Convulsants; Docosahexaenoic Acids; Eicosapentaenoic Acid; Epilepsy; Fatty Acids, Unsaturated; Glutamic Acid; Hippocampus; Male; Mice; Neurons; Neurotoxins; Oleic Acid; Patch-Clamp Techniques; Pentylenetetrazole; Platelet Aggregation Inhibitors; Stearic Acids | 1999 |
n-3 PUFA dietary supplementation inhibits proliferation and store-operated calcium influx in thymoma cells growing in Balb/c mice.
Topics: Animals; Antineoplastic Agents; Calcium Signaling; Cell Division; Dietary Fats, Unsaturated; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Male; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms; Phospholipids; T-Lymphocytes; Thymoma; Thymus Neoplasms | 2000 |
Hydrolysis of anandamide and eicosapentaenoic acid ethanolamide in mouse splenocytes.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cells, Cultured; Chromatography, High Pressure Liquid; Eicosapentaenoic Acid; Endocannabinoids; Female; Hydrolysis; Mice; Mice, Inbred CBA; Polyunsaturated Alkamides; Spleen | 2000 |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats.
Topics: Animals; Blood Coagulation Disorders; Diabetes Mellitus; Eicosapentaenoic Acid; Fibrinolysis; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar | 2000 |
Epigallocatechin gallate increase the prostacyclin production of bovine aortic endothelial cells.
Topics: Animals; Arachidonic Acid; Catechin; Cattle; Cells, Cultured; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Endothelium, Vascular; Epoprostenol; Fibrinolytic Agents; Gallic Acid; Gas Chromatography-Mass Spectrometry; Molecular Structure; Platelet Aggregation Inhibitors; Thromboxanes | 2000 |
Effect of ethyl icosapentate on urinary calcium and oxalate excretion.
Topics: Adult; Aged; Blood Urea Nitrogen; Calcium; Cholesterol; Creatine; Eicosapentaenoic Acid; Female; Humans; Magnesium; Male; Middle Aged; Oxalic Acid; Triglycerides; Uric Acid; Urinary Calculi | 2000 |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves the dysfunction of vascular endothelial and smooth muscle cells in male WBN/Kob rats.
Topics: Animals; Bromodeoxyuridine; Cell Movement; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Endothelium, Vascular; Glucose Tolerance Test; Leukotriene C4; Male; Muscle, Smooth, Vascular; Rats; Rats, Inbred Strains; Rats, Wistar; Time Factors | 2000 |
Dietary effects of eicosapentaenoic and docosahexaenoic acid esters on lipid metabolism and immune parameters in Sprague-Dawley rats.
Topics: Animals; Calcimycin; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Exudates and Transudates; Fatty Acids; Immunoglobulins; Ionophores; Leukotriene B4; Lipid Metabolism; Lipids; Liver; Male; Phospholipids; Rats; Rats, Sprague-Dawley | 2000 |
Effect of eicosapentaenoic acid ethyl ester on hypothyroid function.
Topics: Animals; Cholesterol; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; Humans; Hypothyroidism; Male; Rats; Rats, Wistar; Statistics, Nonparametric; Thyroid Gland; Thyroid Hormones; Thyrotropin; Thyroxine; Triglycerides; Triiodothyronine | 2001 |
Effect of ethyl icosapentaenoate (EPA) on the concentration of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in the carotid artery of cuff-sheathed rabbit models.
Topics: Animals; Arteriosclerosis; Carotid Arteries; Disease Models, Animal; Eicosapentaenoic Acid; Interleukin-1; Muscle, Smooth, Vascular; Rabbits; Tumor Necrosis Factor-alpha | 2001 |
Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in type 2 diabetic model rats with hypertriacylglycerolaemia.
Topics: Abdomen; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Eating; Eicosapentaenoic Acid; Glucose Clamp Technique; Glucose Tolerance Test; Hypertriglyceridemia; Insulin Resistance; Lipid Metabolism; Liver; Male; Oleic Acid; Rats; Rats, Inbred OLETF; Safflower Oil; Triglycerides | 2002 |
[A case of mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), showing temporary improvement during the treatment with eicosapentaenoic acid ethyl ester].
Topics: Aged; Eicosapentaenoic Acid; Humans; Male; MELAS Syndrome; Platelet Aggregation Inhibitors | 2001 |
Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Coagulation Factors; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Fibrinolysis; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Platelet Aggregation Inhibitors; Pravastatin; Statistics, Nonparametric; Treatment Outcome | 2000 |
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Drug Combinations; Eicosapentaenoic Acid; Female; Fenofibrate; Humans; Hypolipidemic Agents; Kidney Diseases; Kidney Glomerulus; Lipids; Lipoproteins; Male; Microscopy, Electron; Nephrotic Syndrome; Niceritrol; Pedigree; Probucol | 2003 |
Effects of water activity and lipid addition on secondary structure of zein in powder systems.
Topics: Eicosapentaenoic Acid; Hydrogen Bonding; Linolenic Acids; Oxidation-Reduction; Powders; Protein Structure, Secondary; Solutions; Spectroscopy, Fourier Transform Infrared; Water; Zein | 2003 |
omega-3 Fatty acid for schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Failure | 2003 |
[A study on the contents of fat and fatty acids in five shellfishes].
Topics: Animals; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids; Gas Chromatography-Mass Spectrometry; Pyrones; Shellfish | 2001 |
Omega-3 fatty acids for depression in pregnancy.
Topics: Adult; Depressive Disorder; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2003 |
The effects on plasma, red cell and platelet fatty acids of taking 12 g/day of ethyl-eicosapentaenoate for 16 months: dihomogammalinolenic, arachidonic and docosahexaenoic acids and relevance to Inuit metabolism.
Topics: 8,11,14-Eicosatrienoic Acid; Arachidonic Acid; Blood Platelets; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Erythrocytes; Fatty Acids; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Platelet Aggregation Inhibitors; Time Factors | 2003 |
Is eicosapentaenoic acid useful in the treatment of ulcerative colitis in children?
Topics: Child; Colitis, Ulcerative; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Humans; Leukocytes; Leukotriene B4; Neutrophils; Rectum; Recurrence | 2003 |
Effects of highly purified eicosapentaenoic acid on erythrocyte fatty acid composition and leukocyte and colonic mucosa leukotriene B4 production in children with ulcerative colitis.
Topics: Adolescent; Child; Colitis, Ulcerative; Colon; Docosahexaenoic Acids; Eicosapentaenoic Acid; Erythrocyte Membrane; Fatty Acids; Fatty Acids, Omega-6; Female; Humans; Intestinal Mucosa; Leukocytes; Leukotriene B4; Male; Phospholipids; Recurrence | 2003 |
Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Arteries; Blood Coagulation Disorders; Cell Movement; Drug Administration Schedule; Eicosapentaenoic Acid; Endothelium, Vascular; Fibrinolysis; Lipids; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Inbred OLETF; Vascular Endothelial Growth Factor A | 2003 |
Divergent effects of eicosapentaenoic and docosahexaenoic acid ethyl esters, and fish oil on hepatic fatty acid oxidation in the rat.
Topics: Acyl-CoA Oxidase; Animals; Coenzyme A; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; Fatty Acids, Unsaturated; Fish Oils; Lipid Metabolism; Liver; Mitochondria, Liver; Oxidation-Reduction; Palm Oil; Peroxisomes; Phospholipids; Plant Oils; Rats; Triglycerides | 2003 |
Ethyl-eicosapentaenoic acid ingestion prevents corticosterone-mediated memory impairment induced by central administration of interleukin-1beta in rats.
Topics: Administration, Oral; Animals; Corticosterone; Dinoprostone; Eicosapentaenoic Acid; Interleukin-1; Interleukin-10; Male; Memory; Memory Disorders; Rats; Rats, Long-Evans; Space Perception | 2004 |
Omega-3 fatty acid ethyl-eicosapentaenoate, but not soybean oil, attenuates memory impairment induced by central IL-1beta administration.
Topics: Animal Feed; Animals; Coconut Oil; Corticosterone; Diet; Dinoprostone; Eicosapentaenoic Acid; Hippocampus; Interleukin-1; Male; Memory; Neurotransmitter Agents; Plant Oils; Rats; Rats, Wistar; Soybean Oil; Swimming | 2004 |
Dietary ethyl-eicosapentaenoic acid but not soybean oil reverses central interleukin-1-induced changes in behavior, corticosterone and immune response in rats.
Topics: Animals; Anxiety; Behavior, Animal; Body Weight; Corticosterone; Dietary Fats; Dinoprostone; Drug Interactions; Eicosapentaenoic Acid; Immune System; Injections, Intraventricular; Interleukin-1; Interleukin-10; Male; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Soybean Oil; Stress, Psychological | 2004 |
Effects of protein and peptide addition on lipid oxidation in powder model system.
Topics: Capsules; Eicosapentaenoic Acid; Free Radical Scavengers; Gelatin; Lipid Peroxidation; Peptides; Polysaccharides; Powders; Soybean Proteins | 2005 |
Antitumor and antimetastatic actions of eicosapentaenoic acid ethylester and its by-products formed during accelerated stability testing.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Eicosapentaenoic Acid; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Platelet Aggregation Inhibitors | 2005 |
Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
Topics: Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Exploratory Behavior; Gene Expression Regulation; Huntington Disease; Immunohistochemistry; Mice; Motor Activity; Nerve Degeneration; Phosphopyruvate Hydratase; Time Factors | 2005 |
Effects of the addition of amino acids and peptides on lipid oxidation in a powdery model system.
Topics: Amino Acids; Antioxidants; Capsules; Chromatography, Gas; Eicosapentaenoic Acid; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Lipid Peroxidation; Oxidation-Reduction; Peptides; Polysaccharides; Powders; Solutions | 2005 |
Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Eicosapentaenoic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperbilirubinemia; Muscle, Skeletal; Platelet Aggregation Inhibitors; Pravastatin; Rats; Rhabdomyolysis; Severity of Illness Index; Treatment Outcome | 2006 |
Ethyl-eicosapentaenoic acid in bipolar depression.
Topics: Antipsychotic Agents; Bipolar Disorder; Eicosapentaenoic Acid; Humans; Treatment Outcome | 2006 |
Identification of inflammatory and proresolving lipid mediators in bone marrow and their lipidomic profiles with ovariectomy and omega-3 intake.
Topics: Animals; Bone Marrow; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Inflammation; Lipid Metabolism; Lipids; Lipoxins; Lipoxygenase; Mass Spectrometry; Ovariectomy; Rats | 2008 |
Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats.
Topics: Adipose Tissue, White; Animals; Apelin; Blood Glucose; Carrier Proteins; Diet; Eicosapentaenoic Acid; Gene Expression; Glucokinase; Glucose Transporter Type 1; Glucose Transporter Type 4; Glucose-6-Phosphatase; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Intra-Abdominal Fat; Liver; Male; Muscle, Skeletal; Nicotinamide Phosphoribosyltransferase; Overweight; Rats; Rats, Wistar; Receptor, Insulin; RNA, Messenger; Stimulation, Chemical | 2009 |
Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion.
Topics: Animals; Blood Glucose; Colon; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Gastric Mucosa; Glucagon-Like Peptide 1; Hypoglycemic Agents; Insulin; Jejunum; Linoleic Acid; Male; Mice; Mice, Inbred Strains; Stomach | 2008 |
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment.
Topics: Analysis of Variance; Animals; Celecoxib; Corticosterone; Corticotropin-Releasing Hormone; Cyclooxygenase Inhibitors; Depressive Disorder; Dinoprostone; Disease Models, Animal; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Exploratory Behavior; Gene Expression Regulation; Hippocampus; Interleukin-1; Male; Maze Learning; Nerve Growth Factor; Olfactory Bulb; Phospholipases A2; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides | 2009 |
Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice.
Topics: Animals; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids, Monounsaturated; Fatty Liver; Gene Expression; Male; Mice; Mice, Inbred C57BL; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Sucrose; Triglycerides | 2009 |
Effects of dietary omega-3 fatty acids on ventricular function in dogs with healed myocardial infarctions: in vivo and in vitro studies.
Topics: Animals; Calcium; Dietary Supplements; Disease Models, Animal; Docosahexaenoic Acids; Dogs; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Female; Heart Ventricles; Male; Myocardial Contraction; Myocardial Infarction; Myocardium; Patch-Clamp Techniques; Ultrasonography; Ventricular Function, Left | 2010 |
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Topics: Administration, Oral; Capsules; Carotid Artery Diseases; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Endarterectomy, Carotid; Foam Cells; Gene Expression Regulation; Humans; Inflammation; Inflammation Mediators; Matrix Metalloproteinases; Phospholipids; Preoperative Care; Rupture, Spontaneous; T-Lymphocytes; Treatment Outcome | 2010 |
Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis Regulatory Proteins; Brain; Brain Chemistry; Corpus Striatum; Cyclooxygenase 2; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Frontal Lobe; In Vitro Techniques; Inflammation Mediators; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Parkinson Disease, Secondary; Phospholipases A2, Cytosolic; RNA, Messenger | 2010 |
Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice.
Topics: Animals; Corpus Striatum; Cystamine; Disease Models, Animal; Eicosapentaenoic Acid; Huntington Disease; Injections, Intraventricular; Malonates; Mice; Neuroprotective Agents; Treatment Outcome | 2011 |
Protective effects of prescription n-3 fatty acids against impairment of spatial cognitive learning ability in amyloid β-infused rats.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cerebral Cortex; Cerebral Ventricles; Cognition Disorders; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Hippocampus; Lipid Peroxides; Male; Maze Learning; Rats; Rats, Wistar; Reactive Oxygen Species | 2011 |
Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease.
Topics: Animals; Biogenic Monoamines; Brain; Cyclooxygenase 2; Cytokines; Eicosapentaenoic Acid; Exploratory Behavior; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Humans; Inflammation; Male; Maze Learning; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Parkinsonian Disorders; Phospholipases A2, Cytosolic; Probenecid; Rotarod Performance Test | 2012 |
Ethyl-eicosapentaenoic acid ameliorates the clinical course of experimental allergic encephalomyelitis induced in dark agouti rats.
Topics: Animals; CD4-Positive T-Lymphocytes; Central Nervous System; Diet; Eicosapentaenoic Acid; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Interleukin-2 Receptor alpha Subunit; Male; Myelin Proteins; Myelin Sheath; Rats; Specific Pathogen-Free Organisms; Up-Regulation | 2013 |
Icosapent ethyl for the treatment of hypertriglyceridemia.
Topics: Dietary Supplements; Drug Approval; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Hippocampus; Lipid Peroxides; Male; Maze Learning; Memory; Metabolic Syndrome; Rats; Rats, Inbred SHR | 2013 |
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Topics: Arachidonic Acid; Cell Membrane; Double-Blind Method; Eicosapentaenoic Acid; Erythrocytes; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2013 |
New therapeutic alternatives for the management of dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Benzimidazoles; Coronary Disease; Drug Approval; Eicosapentaenoic Acid; Humans; Hypercholesterolemia; Oligonucleotides; United States; United States Food and Drug Administration | 2013 |
Assessing the clinical benefits of lipid-disorder drugs.
Topics: Cholesterol; Drug Approval; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; United States; United States Food and Drug Administration | 2014 |
Oral administration of eicosapentaenoic acid or docosahexaenoic acid modifies cardiac function and ameliorates congestive heart failure in male rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dietary Supplements; Disease Models, Animal; Docosahexaenoic Acids; Eicosapentaenoic Acid; Electrocardiography; Heart Failure; Heart Ventricles; Leukocytes, Mononuclear; Male; Organ Size; Rats; Rats, Sprague-Dawley; Survival Analysis; Ventricular Dysfunction, Right | 2014 |
A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients.
Topics: Aged; Azetidines; Eicosapentaenoic Acid; Esters; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; New York; Random Allocation; Retrospective Studies | 2014 |
n-3 PUFA induce microvascular protective changes during ischemia/reperfusion.
Topics: Animals; Anti-Inflammatory Agents; Capillary Permeability; Cricetinae; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fish Oils; Leukocyte Rolling; Male; Microvessels; Olive Oil; Plant Oils; Protective Agents; Reperfusion Injury; Triglycerides | 2015 |
Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.
Topics: Administration, Oral; Adult; Atorvastatin; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
To treat or not to treat? Questions, controversies in prevention.
Topics: Cardiology; Cardiovascular Diseases; Congresses as Topic; Coronary Disease; Decision Making; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Societies, Medical; Triglycerides | 2014 |
The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
Topics: Advertising; Drug Industry; Eicosapentaenoic Acid; Hypolipidemic Agents; Legislation as Topic; Legislation, Drug; Off-Label Use; United States; United States Food and Drug Administration | 2015 |
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Topics: Adult; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertriglyceridemia; Hypothyroidism; Lipids; Male; Risk Factors | 2015 |
Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3.
Topics: Administration, Oral; Alprostadil; Animals; Biological Transport; Colon; Dinoprostone; Eicosapentaenoic Acid; Female; Gastric Mucosa; HEK293 Cells; Humans; Kidney; Kinetics; Liver-Specific Organic Anion Transporter 1; Lung; Mice, Knockout; Mutation; Organic Anion Transporters; Tissue Distribution; Transfection | 2016 |
Free Speech and Pharmaceutical Regulation -- Fishy Business.
Topics: Cardiovascular Diseases; Direct-to-Consumer Advertising; Drug Approval; Drug Industry; Drugs, Investigational; Eicosapentaenoic Acid; Humans; Hypolipidemic Agents; Information Dissemination; Legislation as Topic; Legislation, Drug; Off-Label Use; Secondary Prevention; United States; United States Food and Drug Administration | 2016 |
Amarin files patent infringement suit on lipid-lowering drug.
Topics: Drug Industry; Drugs, Generic; Eicosapentaenoic Acid; Hypolipidemic Agents; Patents as Topic; United Kingdom | 2014 |
Flutamide-induced photoleukomelanoderma.
Topics: Administration, Cutaneous; Aged; Androgen Antagonists; Benzimidazoles; Biopsy; Biphenyl Compounds; Bisoprolol; Clopidogrel; Drug Eruptions; Eicosapentaenoic Acid; Ezetimibe; Flutamide; Glucocorticoids; Humans; Male; Patch Tests; Photosensitivity Disorders; Prostatic Neoplasms; Skin Pigmentation; Sunlight; Tetrazoles; Ticlopidine; Ursodeoxycholic Acid; Withholding Treatment | 2016 |
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
Topics: Drug Approval; Drug Industry; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Jurisprudence; Marketing; Off-Label Use; United States; United States Food and Drug Administration | 2016 |
Serum n-3 polyunsaturated fatty acids are inversely associated with longitudinal changes in depressive symptoms during pregnancy.
Topics: Adult; Brazil; Depression; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Humans; Poverty; Pregnancy; Pregnancy Trimesters; Prevalence; Prospective Studies; Psychiatric Status Rating Scales; Young Adult | 2017 |
Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements.
Topics: Cholesterol; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Male; Middle Aged; Triglycerides | 2016 |
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
Topics: Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Erythrocytes; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Triglycerides | 2016 |
Comparative analysis of the efficacy of omega-3 fatty acids for hypertriglyceridaemia management in Korea.
Topics: Disease Management; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Republic of Korea; Retrospective Studies; Triglycerides | 2016 |
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, LDL; Docosahexaenoic Acids; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Triglycerides | 2016 |
Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Dietary Supplements; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans | 2017 |
Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
Topics: Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Prodrugs; Therapeutic Equivalency; Triglycerides | 2017 |
Lipid remodeling and an altered membrane-associated proteome may drive the differential effects of EPA and DHA treatment on skeletal muscle glucose uptake and protein accretion.
Topics: Animals; Carbohydrate Metabolism; Cell Membrane; Cells, Cultured; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Glucose; Lipid Metabolism; Membrane Proteins; Mice; Muscle, Skeletal; Proteome; Triglycerides | 2018 |
Effects of Omega-3 in the treatment of violent schizophrenia patients.
Topics: Adult; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Humans; Male; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Violence; Young Adult | 2018 |
Maternal dietary n-6 polyunsaturated fatty acid deprivation does not exacerbate post-weaning reductions in arachidonic acid and its mediators in the mouse hippocampus.
Topics: Animals; Arachidonic Acid; Eicosapentaenoic Acid; Fatty Acids, Omega-6; Female; Hippocampus; Male; Maternal Nutritional Physiological Phenomena; Mice, Inbred C57BL; Phospholipids; Pregnancy; Prenatal Nutritional Physiological Phenomena; Weaning | 2019 |
Influence of batch-specific biochemical egg characteristics on embryogenesis and hatching success in farmed pikeperch.
Topics: Animals; Aquaculture; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Embryonic Development; Fatty Acids; Fatty Acids, Unsaturated; Female; Ovum; Perches; Reproduction | 2018 |
Eicosapentaenoic acid ethyl ester ameliorates atopic dermatitis-like symptoms in special diet-fed hairless mice, partly by restoring covalently bound ceramides in the stratum corneum.
Topics: Administration, Oral; Animals; Biological Availability; Ceramides; Dermatitis, Atopic; Diet; Disease Models, Animal; Eczema; Eicosapentaenoic Acid; Epidermis; Female; Mice; Mice, Hairless; Permeability; Pruritus; Skin | 2018 |
Effect of dietary omega-3 fatty acid supplementation on frailty-related phenotypes in older adults: a systematic review and meta-analysis protocol.
Topics: Aged; Biomarkers; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Frail Elderly; Frailty; Hand Strength; Humans; Meta-Analysis as Topic; Phenotype; Research Design; Systematic Reviews as Topic | 2018 |
Eicosapentaenoic acid ethyl ester improves endothelial dysfunction in type 2 diabetic mice.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Blood Glucose; Cardiovascular Agents; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Eicosapentaenoic Acid; Endothelium, Vascular; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle Contraction; Nitroprusside; Phenylephrine; Tissue Culture Techniques; Vasodilation | 2018 |
Immunoregulatory role of 15-lipoxygenase in the pathogenesis of bacterial keratitis.
Topics: Animals; Arachidonate 15-Lipoxygenase; Eicosapentaenoic Acid; Inflammation; Inflammation Mediators; Keratitis; Lipid Metabolism; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neutrophils | 2018 |
Production of fucoxanthin, chrysolaminarin, and eicosapentaenoic acid by Odontella aurita under different nitrogen supply regimes.
Topics: beta-Glucans; Cell Culture Techniques; Culture Media; Diatoms; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Glycolipids; Microalgae; Nitrogen; Xanthophylls | 2018 |
Adipose tissue fatty acid composition and cognitive impairment.
Topics: Adipose Tissue; Aged, 80 and over; Arachidonic Acid; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Humans; Incidence; Male; Prevalence; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Sweden | 2018 |
Plasma Concentrations of Long Chain N-3 Fatty Acids in Early and Mid-Pregnancy and Risk of Early Preterm Birth.
Topics: Adolescent; Adult; Case-Control Studies; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Middle Aged; Odds Ratio; Pregnancy; Premature Birth; Risk Factors; Young Adult | 2018 |
Maternal omega-3 polyunsaturated fatty acid supplementation on offspring hip joint conformation.
Topics: Animals; Body Weight; Diet; Dietary Supplements; Docosahexaenoic Acids; Dogs; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Female; Hip Joint; Male; Maternal Nutritional Physiological Phenomena; Pregnancy; Species Specificity; Weaning | 2018 |
Enzymatic synthesis and chemical inversion provide both enantiomers of bioactive epoxydocosapentaenoic acids.
Topics: Cytochrome P-450 Enzyme System; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Oxidation-Reduction; Stereoisomerism | 2018 |
Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Drug Therapy, Combination; Eicosapentaenoic Acid; Fatty Acids; Fish Oils; Humans; Hypoglycemic Agents; Insulin; Lipogenesis; Liver; Male; Mice; Pioglitazone | 2018 |
[Separation of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester by simulated moving bed chromatography].
Topics: Chromatography, High Pressure Liquid; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3 | 2018 |
Fermentation performance and metabolomic analysis of an engineered high-yield PUFA-producing strain of Schizochytrium sp.
Topics: Bioengineering; Biomarkers; Bioreactors; Biotechnology; Cell Proliferation; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fermentation; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Glucose; Glutamine; Lipid Metabolism; Lipids; Metabolomics; Multivariate Analysis; Proline; Stramenopiles | 2019 |
Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline?
Topics: Activities of Daily Living; Aged; Cognition; Cognitive Dysfunction; Dementia; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Erythrocytes; Fatty Acids, Omega-3; Female; Humans; Male; Memory; Placebos; Retrospective Studies; Walking Speed | 2018 |
Oleogel-structured composite for the stabilization of ω3 fatty acids in fish oil.
Topics: beta-Cyclodextrins; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Fish Oils; Humans; Hydrogen-Ion Concentration; Male; Molecular Structure; Organic Chemicals; Spectroscopy, Fourier Transform Infrared; Taste; Thermogravimetry | 2018 |
Profile and distribution of fatty acids in edible parts of commonly consumed marine fishes in Chile.
Topics: Animals; Aquatic Organisms; Chile; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Fish Products; Fishes; Perciformes; Triglycerides | 2019 |
Enhancement of dairy sheep cheese eating quality with increased n-3 long-chain polyunsaturated fatty acids.
Topics: alpha-Linolenic Acid; Animal Feed; Animals; Breeding; Cheese; Dairying; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Linseed Oil; Milk; Plant Oils; Pregnancy; Rumen; Sheep | 2019 |
5-lipoxygenase-dependent biosynthesis of novel 20:4 n-3 metabolites with anti-inflammatory activity.
Topics: Anti-Inflammatory Agents; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Eicosapentaenoic Acid; Female; HEK293 Cells; Humans; Hydroxyeicosatetraenoic Acids; Leukotriene B4; Male; Neutrophils | 2018 |
Fat-1 Transgene Is Associated With Improved Reproductive Outcomes.
Topics: Animals; Arachidonic Acid; Diet, High-Fat; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Female; Fertility; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pregnancy; Reproduction; Transgenes | 2018 |
FISHing for the Miracle of Eicosapentaenoic Acid.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Maternal eicosapentaenoic acid feeding promotes placental angiogenesis through a Sirtuin-1 independent inflammatory pathway.
Topics: Angiogenesis Inducing Agents; Animals; Diet, High-Fat; Dietary Supplements; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Inflammation; Insulin Resistance; Male; Maternal Exposure; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Neovascularization, Physiologic; NF-kappa B; Obesity; Placenta; Pregnancy; Sirtuin 1; Tumor Necrosis Factor-alpha | 2019 |
Hypertriglyceridaemia - REDUCE-IT with icosapent ethyl.
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2019 |
Production of eicosapentaenoic acid (EPA, 20:5n-3) in transgenic peanut (Arachis hypogaea L.) through the alternative Δ8-desaturase pathway.
Topics: Arachis; Chromatography, Gas; Eicosapentaenoic Acid; Fatty Acid Desaturases; Oxidoreductases; Plant Leaves; Plants, Genetically Modified; Protein Engineering; Recombinant Proteins; Seeds | 2019 |
Patatin-like lipolytic acyl hydrolases and galactolipid metabolism in marine diatoms of the genus Pseudo-nitzschia.
Topics: Diatoms; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Galactolipids; Hydrolases; Lipid Metabolism; Lipolysis; Lipoxygenase; Microalgae; Oxylipins | 2019 |
A Novel Dietary Source of EPA and DHA: Metabolic Engineering of an Important Freshwater Species-Common Carp by fat1-Transgenesis.
Topics: Animals; Animals, Genetically Modified; Cadherins; Carps; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gene Transfer Techniques; Male; Nutritive Value | 2019 |
Adaptive evolution of microalgal strains empowered by fulvic acid for enhanced polyunsaturated fatty acid production.
Topics: Benzopyrans; Diatoms; Eicosapentaenoic Acid; Microalgae; Temperature | 2019 |
Effect of Dietary Partial Hydrolysate of Phospholipids, Rich in Docosahexaenoic Acid-Bound Lysophospholipids, on Lipid and Fatty Acid Composition in Rat Serum and Liver.
Topics: Acyl-CoA Oxidase; Animals; Cholesterol; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fish Oils; Liver; Lysophospholipids; Male; Phospholipids; Rats; Rats, Wistar; Soybean Oil; Triglycerides | 2019 |
Effect of psychiatric drugs on Daphnia magna oxylipin profiles.
Topics: Animals; Daphnia; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Linoleic Acid; Oxylipins; Psychotropic Drugs; Water Pollutants, Chemical | 2018 |
Growth and Biochemical Composition of
Topics: Arachidonic Acid; Biomass; Culture Media; Eicosapentaenoic Acid; Fatty Acids; Nitrogen; Phycoerythrin; Porphyridium | 2019 |
Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
Topics: Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Eicosapentaenoic Acid; Female; Humans; Lipid Regulating Agents; Male; Middle Aged; Myocardial Infarction; Retrospective Studies | 2019 |
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial.
Topics: Atherosclerosis; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Drug Costs; Dyslipidemias; Eicosapentaenoic Acid; Eligibility Determination; Humans; Hypolipidemic Agents; Lipids; Multicenter Studies as Topic; Patient Selection; Risk Factors; Treatment Outcome; United States; United States Department of Veterans Affairs; Veterans Health Services | 2019 |
Novel antibody-based reversal agent for ticagrelor.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticagrelor | 2019 |
Comparison of Fatty Acid Profiles in a Group of Female Patients with Chronic Kidney Diseases (CKD) and Metabolic Syndrome (MetS)⁻Similar Trends of Changes, Different Pathophysiology.
Topics: Arachidonic Acid; Chromatography, Gas; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Monounsaturated; Female; Humans; Metabolic Syndrome; Oleic Acid; Renal Insufficiency, Chronic | 2019 |
Omega-3 polyunsaturated fatty acid intake norms and preterm birth rate: a cross-sectional analysis of 184 countries.
Topics: Adult; alpha-Linolenic Acid; Cross-Sectional Studies; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Internationality; Linear Models; Pregnancy; Premature Birth; Young Adult | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Risk Factors | 2019 |
Prepartum fatty acid supplementation in sheep. IV. Effect of calcium salts with eicosapentaenoic acid and docosahexaenoic acid in the maternal and finishing diet on lamb liver and adipose tissue during the lamb finishing period1.
Topics: Adipose Tissue; Animal Feed; Animals; Calcium; Diet; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Nonesterified; Female; Lipogenesis; Liver; Male; Parturition; Pregnancy; Random Allocation; Sheep; Weaning | 2019 |
Supplementation with eicosapentaenoic and docosahexaenoic acids in late gestation in ewes changes adipose tissue gene expression in the ewe and growth and plasma concentration of ghrelin in the offspring1.
Topics: Adipose Tissue; Animals; Body Weight; Diet; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Ghrelin; Pregnancy; Sheep; Weaning | 2019 |
Effect of icosapent ethyl on stroke risk: Different strokes for different folks?
Topics: Asian People; Cardiovascular Diseases; Eicosapentaenoic Acid; Ethnicity; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Stroke; White People | 2019 |
Omega-3 fatty acid intake and prevalent respiratory symptoms among U.S. adults with COPD.
Topics: Aged; alpha-Linolenic Acid; Cough; Cross-Sectional Studies; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Logistic Models; Male; Middle Aged; Nutrition Surveys; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Respiratory Sounds; United States | 2019 |
Confirmatory Trials for Drugs Approved on a Single Trial.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Drug Approval; Drug Combinations; Eicosapentaenoic Acid; Evidence-Based Medicine; Heart Failure; Humans; Neprilysin; Protease Inhibitors; Research Design; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Editorial commentary: Icosapent ethyl in the treatment and prevention of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans | 2020 |
Redox status and fatty acid composition of Mactra corallina digestive gland following exposure to acrylamide.
Topics: Acrylamide; Animals; Antioxidants; Arachidonic Acid; Bivalvia; Catalase; Digestion; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Glutathione; Linoleic Acid; Oxidation-Reduction; Oxidative Stress; Superoxide Dismutase | 2019 |
Risk of Total Events With Icosapent Ethyl: Can We Reduce It?
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2019 |
Synergistic effect of sea cucumber saponins and EPA-enriched phospholipids on insulin resistance in high-fat diet-induced obese mice.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Chemokine CCL2; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Eicosapentaenoic Acid; Glucose; Glucose Intolerance; Glucose Tolerance Test; Insulin; Insulin Resistance; Interleukin-6; Lipid Metabolism; Lipids; Lipolysis; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Phospholipids; Saponins; Sea Cucumbers; Tumor Necrosis Factor-alpha | 2019 |
Omega-3-rich Isochrysis sp. biomass enhances brain docosahexaenoic acid levels and improves serum lipid profile and antioxidant status in Wistar rats.
Topics: Animals; Antioxidants; Brain; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Gene Expression; Haptophyta; Lipids; Liver; Male; Microalgae; Rats; Rats, Wistar | 2019 |
The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
Topics: Australia; Cardiovascular Diseases; Cost-Benefit Analysis; Delivery of Health Care; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Male; Middle Aged | 2019 |
Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.
Topics: Adult; Animals; Arachidonic Acid; Brain; Depression; Depressive Disorder, Major; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Humans; Linear Models; Male; Middle Aged; Positron-Emission Tomography; Serotonin Plasma Membrane Transport Proteins | 2019 |
Point of purchase fatty acid profile, oxidative status and quality of vacuum-packaged grass fed Australian beef held chilled for up to 12 weeks.
Topics: Animals; Australia; Biomarkers; Cattle; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Food Storage; Oxidation-Reduction; Red Meat; Refrigeration; Shear Strength; Vacuum | 2019 |
Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles.
Topics: Eicosapentaenoic Acid; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Triglycerides | 2019 |
Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome - Evaluation of awareness and implementation among Croatian oncologists.
Topics: Cachexia; Eicosapentaenoic Acid; Humans; Megestrol Acetate; Neoplasms; Nutritional Support; Oncologists; Surveys and Questionnaires; Syndrome | 2019 |
Adipokines secretion in feline primary adipose tissue culture in response to dietary fatty acids.
Topics: Adipokines; Adipose Tissue; Animals; Arachidonic Acid; Body Constitution; Cats; Cells, Cultured; Dietary Fats; Eicosapentaenoic Acid; Fatty Acids; Female; Interleukin-6; Palmitic Acid; Troglitazone; Tumor Necrosis Factor-alpha | 2019 |
Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial.
Topics: Biomarkers; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Lipid Regulating Agents; Male; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2019 |
Antioxidant and Cardioprotective Effects of EPA on Early Low-Severity Sepsis through UCP3 and SIRT3 Upholding of the Mitochondrial Redox Potential.
Topics: Animals; Antioxidants; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Mitochondria; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Sepsis; Sirtuin 3; Uncoupling Protein 3 | 2019 |
Chlorpyrifos-induced dysfunction of lipid metabolism is not restored by supplementation of polyunsaturated fatty acids EPA and ARA in Atlantic salmon liver cells.
Topics: Animals; Arachidonic Acid; Cells, Cultured; Chlorpyrifos; Eicosapentaenoic Acid; Glutathione; Hepatocytes; Insecticides; Lipid Metabolism; Male; Oxidative Stress; Salmo salar | 2019 |
Ischemic Event Reduction and Triglycerides.
Topics: Brain Ischemia; Eicosapentaenoic Acid; Humans; Stroke; Triglycerides | 2019 |
Preparation of eicosapentaenoic acid ethyl ester from fish oil ethyl esters by continuous batch chromatography.
Topics: Countercurrent Distribution; Eicosapentaenoic Acid; Fish Oils | 2019 |
Modification of nutritional values and flavor qualities of muscle of swimming crab (Portunus trituberculatus): Application of a dietary lipid nutrition strategy.
Topics: Animals; Brachyura; Dietary Fats; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Flavoring Agents; Gas Chromatography-Mass Spectrometry; Nutritional Status; Nutritive Value; Seafood; Solid Phase Microextraction; Swimming; Taste | 2020 |
Comparison of the Fatty Acid and Triglyceride Profiles of Big Eye Tuna (
Topics: Animals; Carps; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Salmo salar; Triglycerides; Tuna | 2019 |
Molecular dynamics simulations of the interaction of wild type and mutant human CYP2J2 with polyunsaturated fatty acids.
Topics: Arachidonic Acid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme System; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; HEK293 Cells; Humans; Models, Chemical; Molecular Docking Simulation; Mutation | 2019 |
Evaluating the use of fish oil microcapsules as omega-3 vehicle in cooked and dry-cured sausages as affected by their processing, storage and cooking.
Topics: Animals; Capsules; Chickens; Cooking; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fish Oils; Food Handling; Food Storage; Meat Products; Oxidation-Reduction; Swine | 2020 |
Concentration-Dependent Effects of N-3 Long-Chain Fatty Acids on Na,K-ATPase Activity in Human Endothelial Cells.
Topics: Atherosclerosis; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial Cells; Homeostasis; Humans; Membrane Fluidity; Sodium-Potassium-Exchanging ATPase | 2019 |
Modulation of the Liver Protein Carbonylome by the Combined Effect of Marine Omega-3 PUFAs and Grape Polyphenols Supplementation in Rats Fed an Obesogenic High Fat and High Sucrose Diet.
Topics: Animals; Diet, High-Fat; Dietary Sucrose; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Liver; Obesity; Oxidative Stress; Polyphenols; Protein Carbonylation; Proteins; Proteomics; Rats; Rats, Inbred WKY; Vitis | 2019 |
Eicosapentaenoic acid-enriched phospholipids suppressed lipid accumulation by specific inhibition of lipid droplet-associated protein FSP27 in mice.
Topics: Adipose Tissue, White; Animals; Anti-Obesity Agents; Cholesterol; Eicosapentaenoic Acid; Fatty Acids, Nonesterified; Gene Expression Regulation; Lipid Droplets; Lipolysis; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phospholipids; Proteins; RNA, Messenger; Triglycerides | 2020 |
A biphasic system based on guanidinium ionic liquid: Preparative separation of eicosapentaenoic acid ethyl ester and docosahexaenoic acid ethyl ester by countercurrent chromatography.
Topics: Chemistry Techniques, Analytical; Countercurrent Distribution; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fish Oils; Guanidine; Heptanes; Ionic Liquids; Methanol; Solvents | 2020 |
Reduction of cardiovascular risk with icosapent ethyl (Vascepa).
Topics: Cardiovascular Diseases; Drug Administration Schedule; Drug Interactions; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Liver Transcriptome Profiling Reveals That Dietary DHA and EPA Levels Influence Suites of Genes Involved in Metabolism, Redox Homeostasis, and Immune Function in Atlantic Salmon (Salmo salar).
Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Aquaculture; Diet; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Gene Expression Profiling; Homeostasis; Lipid Metabolism; Liver; Oxidation-Reduction; Salmo salar | 2020 |
Epidemiological Features and Clinical Presentations of Acute Coronary Syndrome in Young Patients.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Arachidonic Acid; Eicosapentaenoic Acid; Female; Humans; Japan; Male; Middle Aged; Overweight; Prevalence; Registries; Retrospective Studies; Risk Factors; Smoking | 2020 |
EPA is More Effective than DHA to Improve Depression-Like Behavior, Glia Cell Dysfunction and Hippcampal Apoptosis Signaling in a Chronic Stress-Induced Rat Model of Depression.
Topics: Animals; Apoptosis; Behavior, Animal; Depressive Disorder; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Hippocampus; Neuroglia; Rats; Rats, Sprague-Dawley; Stress, Psychological | 2020 |
Triglyceride lowering drugs: not just icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Pharmaceutical Preparations; Triglycerides | 2020 |
Reducing Cardiovascular Disease Risk in Women Beyond Statin Therapy: New Insights 2020.
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Eicosapentaenoic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Male; Middle Aged; Triglycerides | 2020 |
Application of the cbh1 promoter in Mortierella alpina and optimization of induction conditions.
Topics: Arachidonic Acid; Cellulose 1,4-beta-Cellobiosidase; Eicosapentaenoic Acid; Fatty Acid Desaturases; Fatty Acids, Unsaturated; Gene Expression; Genes, Reporter; Genetic Engineering; Mortierella; Promoter Regions, Genetic | 2020 |
LC-APCI-MS/MS assay for quantitation of ethyl esters of eicosapentaenoic acid and docosahexaenoic acid in human plasma and its application in a pharmacokinetic study.
Topics: Administration, Oral; Chromatography, Liquid; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Humans; Limit of Detection; Linear Models; Reproducibility of Results; Tandem Mass Spectrometry | 2020 |
Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
Topics: Age Factors; Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Early Termination of Clinical Trials; Eicosapentaenoic Acid; Hemorrhage; Humans; Medicare; Models, Economic; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; United States | 2020 |
Eicosapentaenoic and docosahexaenoic acid supplementation during early gestation modified relative abundance on placenta and fetal liver tissue mRNA and concentration pattern of fatty acids in fetal liver and fetal central nervous system of sheep.
Topics: Animals; Central Nervous System; Dietary Supplements; DNA (Cytosine-5-)-Methyltransferases; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acid-Binding Proteins; Fatty Acids; Female; Fetus; Gestational Age; Lipoprotein Lipase; Liver; Placenta; Pregnancy; RNA, Messenger; Sheep | 2020 |
Effect of icosapent ethyl on susceptibility to ventricular arrhythmias in postinfarcted rat hearts: Role of GPR120-mediated connexin43 phosphorylation.
Topics: Animals; Connexin 43; Eicosapentaenoic Acid; Lipid Regulating Agents; Male; Myocardial Infarction; Phosphorylation; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Tachycardia, Ventricular | 2020 |
Growth, fatty, and amino acid profiles of the soil alga Vischeria sp. E71.10 (Eustigmatophyceae) under different cultivation conditions.
Topics: Amino Acids; Biomass; Biotechnology; Culture Media; DNA, Ribosomal; Eicosapentaenoic Acid; Fatty Acids; Germany; Microalgae; Nitrogen; Soil; Stramenopiles | 2020 |
Federal judge invalidates icosapent ethyl patents - but on the basis of a common statistical mistake.
Topics: Data Interpretation, Statistical; Eicosapentaenoic Acid; Humans; Patents as Topic | 2020 |
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus; Eicosapentaenoic Acid; Eligibility Determination; Female; Humans; Lipid Regulating Agents; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Nutrition Surveys; Primary Prevention; Secondary Prevention; Stroke | 2020 |
Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction.
Topics: Adult; Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Risk Reduction Behavior | 2021 |
Polyunsaturated fatty acids and p38-MAPK link metabolic reprogramming to cytoprotective gene expression during dietary restriction.
Topics: Animals; Biochemical Phenomena; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Gene Expression Regulation; Gene Knockdown Techniques; Linoleic Acid; Longevity; Metabolic Networks and Pathways; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases | 2020 |
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M
Topics: Cilostazol; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Eicosapentaenoic Acid; Epoprostenol; Humans; Iloprost; Molecular Docking Simulation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration | 2021 |
The therapy with icosapent ethyl after the EVAPORATE trial: Between hope and skepticism.
Topics: Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension | 2020 |
Can EPA evaporate plaques?
Topics: Coronary Artery Disease; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Triglycerides | 2020 |
Dietary exposure assessment of methylmercury and polyunsaturated fatty acids in saltwater fish and processed foods among Taiwanese women of child-bearing age and children: A novel core food-matching approach.
Topics: Adult; Animals; Child; Cooking; Dietary Exposure; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Fishes; Humans; Methylmercury Compounds; Middle Aged; Public Health; Risk Assessment; Seafood; Taiwan | 2021 |
Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment.
Topics: Aged; COVID-19 Drug Treatment; Eicosapentaenoic Acid; Humans; Male; Young Adult | 2020 |
Icosapent Ethyl (Vascepa) for Hyperlipidemia/Hypercholesterolemia to Reduce Risk of Heart Attack and Stroke.
Topics: Eicosapentaenoic Acid; Humans; Hypercholesterolemia; Lipid Regulating Agents; Myocardial Infarction; Stroke | 2021 |
Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
Topics: Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Primary Prevention; Risk Factors; Secondary Prevention; Triglycerides | 2021 |
High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction.
Topics: 8,11,14-Eicosatrienoic Acid; Aged; Aged, 80 and over; Arachidonic Acid; Cause of Death; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Unsaturated; Female; Heart Failure; Humans; Male; Nutritional Status; Plasma; Prognosis; Retrospective Studies; Risk Factors; Stroke Volume | 2021 |
The need for precision nutrition, genetic variation and resolution in Covid-19 patients.
Topics: COVID-19; Docosahexaenoic Acids; Eicosanoids; Eicosapentaenoic Acid; Fatty Acids, Essential; Fatty Acids, Omega-3; Genetic Predisposition to Disease; Haplotypes; Humans; Inflammation; Linoleic Acid; RNA, Viral; SARS-CoV-2 | 2021 |
Plasma phospholipid n-3 polyunsaturated fatty acids and major depressive disorder in Japanese elderly: the Japan Public Health Center-based Prospective Study.
Topics: Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Depressive Disorder, Major; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Fatty Acids, Unsaturated; Female; Humans; Japan; Male; Odds Ratio; Phospholipids; Prospective Studies; Risk Factors | 2021 |
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Topics: Adult; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dietary Supplements; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Female; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Pregnancy; Pregnancy Complications; Primary Prevention; Risk Assessment; Secondary Prevention | 2021 |
Intrauterine Transfer of Polyunsaturated Fatty Acids in Mother-Infant Dyads as Analyzed at Time of Delivery.
Topics: Arachidonic Acid; Cross-Sectional Studies; Eicosapentaenoic Acid; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Female; Fetal Blood; Fetal Development; Fetus; Humans; Infant; Linoleic Acid; Male; Placenta; Pregnancy | 2021 |
A comparative study of the effects of phosphatidylserine rich in DHA and EPA on Aβ-induced Alzheimer's disease using cell models.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; CHO Cells; Cricetulus; Docosahexaenoic Acids; Eicosapentaenoic Acid; Hippocampus; Liposomes; Neurons; Phosphatidylserines | 2021 |
The EVAPORATE trial provides important mechanistic data on plaque characteristics that have relevance to the REDUCE-IT results and clinical use of icosapent ethyl.
Topics: Eicosapentaenoic Acid; Humans; Hypertriglyceridemia; Plaque, Atherosclerotic | 2021 |
Underlying mechanisms involved in the icosapent ethyl reduction of cardiovascular events still cannot be attributed to an anti-atherosclerotic effect.
Topics: Atherosclerosis; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2021 |
Intensive Medical Management to Prevent Large and Small Artery Atherothrombotic Stroke: Time to Expand the Horizon.
Topics: Eicosapentaenoic Acid; Folic Acid; Glucagon-Like Peptide-1 Receptor; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Thrombotic Stroke | 2021 |
Dietary EPA-Enriched Phospholipids Alleviate Chronic Stress and LPS-Induced Depression- and Anxiety-Like Behavior by Regulating Immunity and Neuroinflammation.
Topics: Animals; Anxiety; Behavior, Animal; Brain; Corticosterone; Depression; Disease Models, Animal; Eicosapentaenoic Acid; Kynurenine; Lipopolysaccharides; Male; Mice, Inbred ICR; Neuroinflammatory Diseases; Neurotransmitter Agents; Phospholipids; Spleen; Stress, Psychological | 2021 |
Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk.
Topics: Cardiovascular Diseases; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; PCSK9 Inhibitors; RNA, Small Interfering | 2021 |
The cost-effectiveness of icosapent ethyl in combination with statin therapy compared with statin alone for cardiovascular risk reduction.
Topics: Australia; Cardiovascular Diseases; Cost-Benefit Analysis; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Quality-Adjusted Life Years; Risk Factors | 2021 |
Consumption of Monounsaturated Fatty Acids Is Associated with Improved Cardiometabolic Outcomes in Four African-Origin Populations Spanning the Epidemiologic Transition.
Topics: Adult; Black People; Cardiometabolic Risk Factors; Dietary Fats; Dietary Fiber; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Monounsaturated; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Female; Ghana; Humans; Inflammation; Jamaica; Male; Middle Aged; Obesity; Prospective Studies; Seychelles; United States | 2021 |
Differential and shared effects of eicosapentaenoic acid and docosahexaenoic acid on serum metabolome in subjects with chronic inflammation.
Topics: Cross-Over Studies; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Female; Humans; Inflammation; Male; Metabolome; Middle Aged; Sunflower Oil; Triglycerides | 2021 |
Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT.
Topics: Arm; Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertriglyceridemia; Mineral Oil; Risk Factors | 2021 |
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Risk Factors | 2021 |
SPM pathway marker analysis of the brains of obese mice in the absence and presence of eicosapentaenoic acid ethyl esters.
Topics: Animals; Brain Chemistry; Diet, High-Fat; Disease Models, Animal; Eicosapentaenoic Acid; Lipoxins; Male; Mass Spectrometry; Metabolic Networks and Pathways; Metabolomics; Mice; Mice, Obese; Obesity | 2021 |
An Opportunity to Improve Secondary Prevention With Icosapent Ethyl in Patients Who Have Undergone Coronary Artery Bypass Graft Surgery.
Topics: Adult; Australia; Cardiovascular Diseases; Coronary Artery Bypass; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Retrospective Studies; Secondary Prevention | 2022 |
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipid Regulating Agents; Randomized Controlled Trials as Topic | 2022 |
Successful treatment of severe hypertriglyceridemia with icosapent ethyl in a case of congenital generalized lipodystrophy type 4.
Topics: Adolescent; Eicosapentaenoic Acid; Female; Humans; Hypertriglyceridemia; Lipodystrophy; Lipodystrophy, Congenital Generalized; Muscular Diseases | 2022 |
Optimizing Dyslipidemic Cardiovascular Residual Risk Reduction With Icosapent Ethyl in Post-MI Patients.
Topics: Dyslipidemias; Eicosapentaenoic Acid; Humans; Myocardial Infarction; Risk Reduction Behavior | 2022 |
Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Topics: Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Cost-Benefit Analysis; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Proprotein Convertase 9; Quality-Adjusted Life Years; State Medicine | 2022 |
Should we continue to subsidise therapeutics with uncertain efficacy? Health economic implications for icosapent ethyl.
Topics: Cardiovascular Diseases; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Triglycerides | 2023 |
Pharmacokinetics of Single and Multiple Oral Administration of a Self-emulsifying Formulation of Highly Purified Eicosapentaenoic Acid Ethyl Ester (MND-2119) Compared With the Nonself-emulsifying Formulation in Healthy Male Subjects.
Topics: Administration, Oral; Adult; Biological Availability; Eicosapentaenoic Acid; Fasting; Humans; Male | 2023 |
Icosapent Ethyl Supplementation and Cardiovascular Prevention-Implications of Evolving Data.
Topics: Cardiovascular Diseases; Dietary Supplements; Eicosapentaenoic Acid; Humans; Hypertriglyceridemia | 2022 |
Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hypertriglyceridemia; Risk Factors | 2023 |
Icosapent ethyl alleviates acetic acid-induced ulcerative colitis via modulation of SIRT1 signaling pathway in rats.
Topics: Acetic Acid; Animals; Caspase 3; Colitis; Colitis, Ulcerative; Collagen; Colon; Eicosapentaenoic Acid; Male; Mesalamine; NF-E2-Related Factor 2; NF-kappa B; Rats; Rats, Wistar; Signal Transduction; Sirtuin 1; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53 | 2023 |
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Eicosapentaenoic Acid; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Risk Factors | 2023 |
Prevention of progressive hearing loss in a mouse model of diabetes by oral intake of eicosapentaenoic acid ethyl ester.
Topics: Animals; Cochlea; Deafness; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Eicosapentaenoic Acid; Hearing Loss; Mice; Mice, Obese; Obesity | 2023 |
Icosapent ethyl: insights into cardiovascular residual risk.
Topics: Cardiovascular System; Eicosapentaenoic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2023 |